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ABSTRACT: Lysyl oxidase (LOX) is a secreted copper-
dependent amine oxidase that cross-links collagens and elastin
in the extracellular matrix and is a critical mediator of tumor
growth and metastatic spread. LOX is a target for cancer
therapy, and thus the search for therapeutic agents against
LOX has been widely sought. We report herein the medicinal
chemistry discovery of a series of LOX inhibitors bearing an
aminomethylenethiophene (AMT) scaffold. High-throughput screening provided the initial hits. Structure−activity relationship
(SAR) studies led to the discovery of AMT inhibitors with sub-micromolar half-maximal inhibitory concentrations (IC50) in a
LOX enzyme activity assay. Further SAR optimization yielded the orally bioavailable LOX inhibitor CCT365623 with good
anti-LOX potency, selectivity, pharmacokinetic properties, as well as anti-metastatic efficacy.
■ INTRODUCTION
Lysyl oxidase (LOX) and its family members LOX-like (LOX-
L) 1−4 are copper-dependent amine oxidases that covalently
cross-link collagens and elastin in the tumor extracellular
matrix.1−4 LOX is secreted as a catalytically inactive 50 kDa
pro-protein, which is cleaved to an active 32 kDa enzyme by
proteases such as procollagen C-proteinase. LOX and
LOXL1−4 have variable N-termini, and they share a highly
conserved C-terminus, where the catalytic domain is located.
The catalytic site comprises a copper binding motif and a
covalently bound lysine tyrosylquinone (LTQ) cofactor, where
peptidyl lysine residues (H2NCH2R) are converted to the
corresponding α-aminoadipic-δ-semialdehyde (OCHR) in
an oxidative deamination reaction.3 The newly formed
aldehyde residues undergo spontaneous cross-linking with
adjacent nucleophilic functionalities, leading to the insoluble
extracellular protein matrices.
LOX and LOXL2 also have important roles in promoting
tumor growth in many types of cancer.5−12 In particular, LOX
has been demonstrated to be a critical mediator of cancer
metastasis.13 Therapeutic agents targeting the activity of LOX
are thus proposed as cancer treatments, especially against
metastasis where no effective therapeutic methods are
currently available.
Until recently, no druglike small molecule inhibitors of LOX
itself have been reported. Noticeably, the irreversible inhibitor
β-aminopropionitrile14,15 (BAPN) has found widespread
applications in LOX-family-related biological studies (Figure
1), although the lack of amenable sites for chemical
modification has prevented its development into a clinically
optimal drug. More recently, haloallylamine-based inhibitors
PXS-S1A and PXS-S2A (full structures not disclosed)16 and
trifluoromethyl (CF3)-substituted aminomethylene-pyridine 1
were reported to be potent selective inhibitors of one of the
family members, LOXL2; the latter also showed weak
inhibition against LOX.17,18 Intriguingly, analogues of pyridine
1 without the CF3 functionality were less selective toward
LOXL2, with low micromolar IC50s against LOX.
We have recently reported the elucidation of a mechanism
by which LOX drives tumor progression in breast cancer19 and
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Figure 1. Small molecule inhibitors of LOX-family enzymes.
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that treatment with the aminomethylenethiophene (AMT)
inhibitor CCT365623 (9f) led to significant reduction in
tumor growth and, importantly, in metastatic burden too, in a
LOX-dependent breast tumor transgenic mouse model. In our
current study, we present the medicinal chemistry develop-
ment leading to the discovery of the orally efficacious AMT
inhibitor 9f.
■ RESULTS AND DISCUSSION
LOX Inhibition, Initial SAR. We ran a high-throughput
screen (HTS) at Evotec, of 267 000 diverse compounds and
5000 fragments, on LOX, which yielded a hit rate of 0.4%. (5-
(Piperidin-1-ylsulfonyl)thiophen-2-yl)methanamine 2a was
identified as a positive hit with a mean IC50 of 19 μM. Since
no crystal structure of LOX is available, the design of inhibitors
could not be aided by crystallographic or in silico methods.
Therefore, the SAR of enzyme inhibition is largely elucidated
by introducing systematic modifications to different regions of
the hit molecule.
Substitutions at the 5-Sulfonyl Linker, Sulfonamides. SAR
exploration commenced with the investigation of sulfonamide
substitutions on LOX inhibition (Table 1). Acyclic sulfona-
mides show no improvement (2b and 2c vs 2a), whereas 2-
amido- and 2-hydroxymethylpyrrolidine substitutions exhibit
comparable or better LOX potencies (2d and 2e vs 2a). 2-
Phenylpyrrolidine 2f is also effective against LOX, as is the
bicyclic indoline 2g, which is ∼10-fold more potent than the
piperidine hit 2a. Similarly, tetrahydroquinoline 2h is
equipotent to indoline 2g. Replacement of the piperidine
ring with morpholine does not improve LOX inhibition (2i vs
2a), whereas homopiperazine (2j) substitution leads to ∼2-
fold improvement in IC50. Functionalization of the free
homopiperazine nitrogen with small groups leads to gains in
potency compared with the initial hit, as exemplified in N-
methyl analogue 2k, ethyl urea 2l and, in particular,
sulfonamide 2m.
Substitution at the 5-Sulfonyl Linker, Sulfones. The effect
of alkyl and aryl substitutions at the 5-sulfonyl linker on LOX
inhibition was investigated next (Table 2). Replacements of
the piperidine moiety on HTS hit 2a with cyclohexyl (3a) and
phenyl groups (3b) are beneficial, as are pyridine (3c) and
thiophene (3d). Biphenylsulfone is a weaker inhibitor than the
phenyl analogue (3e vs 3b), whereas 2-naphthalylsulfone 3g is
more potent than the 1-regiosiomer 3f. Methanesulfonamido-
phenyl analogue 3h moderately inhibits LOX, whereas
methanesulfonylphenyl sulfone 3i is an excellent LOX inhibitor
with an IC50 of 0.26 μM, ∼70-fold more potent than the HTS
hit 2a. Replacement of the phenyl moiety of inhibitor 3i with
an alkyl group (3j) leads to a reduction in potency. The SAR
data illustrate that the attachment of cyclic alkyl or aryl groups
to the sulfonyl linker greatly improves LOX potency and the
inhibitory effect is further enhanced by the addition of a
second sulfonyl group.
Modification of the 5-Sulfonyl Linker. The impact of the
sulfonyl linker was subsequently examined (Table 3). A
noticeable correlation can be observed between the electron-
withdrawing ability of the linker and the LOX IC50, with the
most electron-withdrawing sulfonyl group achieving the most
potent inhibition (LOX IC50: 3b < 4a < 4b). Carboxamide
substitution does not improve LOX inhibition (4d vs 4c).
Finally, exchanging the sulfonyl linker and the phenyl ring
leads to reduction in potency (4e vs 3b). It is thus apparent
that the sulfonyl moiety is the optimum linker for the AMT
core and that the electron-withdrawing effect of the linker is
likely to play an important role in the mechanism of inhibition
even though the possibility of H-bond and dipole−dipole
interactions cannot be ruled out.
Table 1. Effects of Sulfonamide Substitution on LOX
Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
Table 2. Effects of Sulfonyl-Alkyl and -Aryl Substitutions on
LOX Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
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Modification of the Thiophene Ring. Aminomethylene-
pyridine 5a is ∼10-fold weaker than the aminomethylenethio-
phene counterpart (Table 4; 5a vs 5b). 1,4-Thiazole 5c is
considerably less potent as an inhibitor than the 1,3-regiomer
5d, whereas 1,3-thiazole 5d demonstrates potency that is
similar to the thiophene 3g. Furan replacement does not
improve the effectiveness of the inhibitors (5e vs 4d).
Additional substitutions on the thiophene ring can potentially
be a useful handle for the development of the series, but the
introduction of a small methyl group is highly unfavorable (5f
vs 2g). Overall, although the replacements of the thiophene
core with some unsubstituted 5-membered heterocycles are
tolerated for LOX inhibition, they are not superior to
thiophene itself.
Modification of the Aminomethylene Moiety. All inhib-
itors contain the aminomethylene moiety (H2NCH2), which
forms a part of the core AMT scaffold. We therefore investigate
a series of modifications to this group where the replacement
moieties are sufficiently diverse for probing noncovalent
interactions, such as H-bond, electrostatic, and dipolar
interactions, while small enough to minimize unfavorable
steric clashes. The SAR data reveals that all substitutions or
modifications at this site result in total loss of activity (Table 5,
6a−6f). It is thus apparent that the aminomethylene moiety
has a unique role in LOX inhibition; it is likely to be involved
in the formation of a Schiff base similar to that of the natural
lysyl substrates.
Next, regiosiomers on the thiophene ring were investigated
(Table 6). Both 2-aminomethyl-3-sulfonyl-thiophene 7a and 3-
aminomethyl-4-sulfonylthiophene 7b show no inhibitory
activity against LOX, whereas 2-aminomethyl-4-sulfonylthio-
phene 7c is a weak inhibitor. Therefore, from these
modifications, the thiophene ring is the optimal ring type
and the aminomethylene and sulfonyl groups are the most
effective substituents when placed on the 2- and 5-positions of
the ring, respectively.
Although the exact mode of binding of these AMT inhibitors
remains unclear due to the absence of a cocrystal structure or a
homology model, the observed SAR suggests that a stable
Schiff base formed from the inhibitor and the LTQ cofactor
(Figure 2) is likely to be involved. Although the formation of
Table 3. Effects of Sulfonyl Linker (X) Modification on LOX
Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
Table 4. Effects of Thiophene Modifications on LOX
Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
Table 5. Effects of Aminomethylene Modifications (R1) on
LOX Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
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the Schiff base is reversible, its stabilization by the sulfonyl
substituent on the thiophene ring by resonance stabilization
and/or direct binding to the enzyme by noncovalent processes,
such as H-bonding, electrostatic, dipolar, or van der Waals
interactions, can lead to a tightly bound enzyme−inhibitor
complex. This can potentially rationalize the improvement in
potency observed in Table 3. The SAR also suggests an
additional noncovalent interaction between the methanesulfo-
nylphenyl moiety and the enzyme, which further enhances the
potency of bis-sulfonyl inhibitors such as compound 9f.
Optimization toward In Vivo-Compatible Inhibitors.
As our aim is to discover LOX inhibitors that can be
administered orally, metabolic stability and pharmacokinetic
(PK) studies were performed on the most promising AMT
inhibitors described above. The highly potent bis-sulfonyl-
phenyl analogue 3i has good stability against mouse micro-
somal (MLM) degradation (Table 9), but its poor detectability
by mass spectrometry renders it unsuitable for in vivo studies.
Bis-sulfonylhomopiperazine 2m also exhibits good anti-LOX
potency, but it cannot be progressed further due to poor
stability against microsomal metabolism. Naphthalenesulfone
3g demonstrates good MLM stability but only moderate
plasma exposure (AUC = 4.2 μM h) when administered orally
in mice at 50 mg/kg. It was apparent that further medicinal
chemistry development was necessary to achieve both potent
LOX inhibition and oral plasma drug exposure compatible with
in vivo studies.
Due to its superior LOX potency and ease of synthesis,
inhibitor 3i was chosen as the platform for the next phase of
discovery. Initial SAR established that modifications of the
aminomethylene group, the thiophene ring, and the sulfonyl
linker were unfavorable to target inhibition. Therefore,
optimization to improve PK properties focused on the aryl
ring and its side-chain substituents. The aim of the subsequent
studies therefore targeted improvement to oral in vivo PK
exposure whilst maintaining/improving LOX potency.
Side-Chain Substitutions. Further SAR studies began with
the investigation of the sulfonyl side-chain substitutions (Table
7). The attachment of the sulfonyl side chain through the 3-
position (with respect to the thiophene sulfone) affords
inhibitors with similar LOX IC50s as the 4-regioisomers (8a vs
3i, 8d vs 8c), whilst 2-substitution is disfavored (8b vs 3i).
Sulfonylpyrrolidines exhibit similar potencies as the methyl
sulfone counterparts (8c−8e vs 3i and 8a), but phenyl sulfone
Table 6. Effects of Regioisomers on the Thiophene Ring on
LOX Potency
aReported IC50 values were determined in at least two separate
experiments (n ≥ 2). When n = 2, individual IC50 values are shown.
When n > 2, the values are reported as the geometric mean with the
error in square brackets expressed as the 95% confidence interval of
the geometric mean.
Figure 2. Proposed binding mode of AMT inhibitors.
Table 7. Effects of Side-Chain Substitutions on LOX Potency of Phenylsulfonyl-AMT Analogues
aReported IC50 values were determined in at least two separate experiments (n ≥ 2). When n = 2, individual IC50 values are shown. When n > 2,
the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval.
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8f is a weaker inhibitor. Small alkyl substituents on the sulfonyl
group are generally well tolerated (8g−8k). Inhibitors 8d, 8e,
and 8j show good anti-LOX potency and MLM stability
(Table 9) and were thus selected for in vivo PK evaluation.
Unfortunately, they have poor plasma exposure in mice when
dosed orally.
Phenyl Ring Substitution. 1,3- and 1,4-Bis-sulfonylphenyl-
AMT inhibitors containing an additional substituent on the 5-
position of the phenyl ring were evaluated against LOX
inhibition (Table 8). All of tert-butyl, tert-butoxy, trimethylsi-
lylethynyl, N-methylpyrazolyl, and pyridinyl substitutions on
the 1,3-bisulfonylphenyl motif lead to moderate reduction in
LOX potency (9a−9e vs 8a), whereas a phenyl substituent is
well tolerated (9f). Replacement of the phenyl group with p-
tolyl affords an equipotent LOX inhibitor (9g vs 9f), but m-
xylyl (9h) and o-ethylphenyl (9i) substitutions are disfavored.
For the 1,4-bis-sulfonylphenyl-AMT motif, all of the N-
methylpyrazolyl (9j), phenyl (9k), and p-tolyl (9l) analogues
exhibit sub-micromolar LOX IC50 values.
In vivo mouse PK studies were then conducted for selected
5-substituted compounds. Both tert-butoxy (9b) and N-
methylpyrazolyl (9j) analogues exhibit low AUCs of 2.3 and
2.8 μM h, respectively (Table 9), although this improves to 6.5
μM h when the oxygen atom of the tert-butoxy group is
removed from the parent compound (9a vs 9b). Pleasingly, the
5-p-tolyl-substituted bis-sulfones have greatly improved and
therapeutically relevant plasma exposures (11 and 12 μM h for
9g and 9l respectively) are obtained. Although the exposure for
5-phenyl-1,4-bis-sulfone 9k is disappointing (AUC = 1.4 μM
h), 5-phenyl-1,3-bis-sulfonyl-AMT 9f achieves a desirable in
vivo PK profile, with the highest AUC, Cmax, longest half-life,
lowest clearance of the series (albeit this is still moderate), and
a respectable intermediate oral bioavailability (F) of 45%.
Table 8. Effects of 5-Substitutions on LOX Potency of Bis-sulfonylphenyl-AMT Analogues
Table 9. In Vitro Mouse Liver Microsome (MLM) Stability and in Vivo Pharmacokinetic (PK) Properties of AMT Inhibitors
compound MLM stability (%)a Cmax(PO) (μM)
b AUC(PO) (μM h)




3i 67 ND ND
8j 91 0.38 0.36
8d 59 0.83 0.22
8e 63 1.5 0.46
9k 41 1.6 1.4
9b 67 6.3 2.3
9j 90 9.6 2.8
3g 100 15 4.2
9a 68 16 6.5
9g 60 6.7 11 67 1.0 39
9l 95 9.4 12 106 0.4 74
9f 65 17 15 49 1.2 45
aMouse liver microsome (MLM) stability values represent the percentage of compound remaining after 30 min; mouse plasma PK parameters were
determined following a single dose by oral gavage (PO) or intravenous injection (IV) at 50 or 10 mg/kg, respectively. bCmax: maximum
concentration. cAUC: area under curve. dCL: clearance. et1/2: half-life.
fF: bioavailability; ND: could not be detected by MS.
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Profile of Orally Available AMT Inhibitors. We have
discovered three AMT inhibitors 9g, 9l, and 9f that are highly
effective in inhibiting LOX activity as well as possessing
therapeutically relevant PK profiles. These compounds are
equally potent inhibitors of LOXL2 (Table 10), which is as
expected due to the highly conserved catalytic site across the
LOX-family members. Pleasingly, all three inhibitors are
inactive against common amine oxidases, including the
copper-containing diamine oxidase (DAO), semicarbazide-
sensitive amine oxidase (SSAO), and the flavin-containing
monoamine oxidases (MAO) A and B. It is noteworthy that
AMT 9f is a substrate of SSAO; thus, SSAO-catalyzed
metabolism could be a potential mechanism of degradation
in vivo.
AMT 9g is a weak inhibitor of the human potassium-ion
channel hERG, whereas inhibitors 9l and 9f are highly
selective. All three inhibitors exhibit high permeability through
colon Caco-2 cells, which is reflected in their good oral
availabilities in mice (Table 9). AMT inhibitor 9f achieves the
most favorable overall profile and was therefore chosen for in
vivo efficacy studies.
Evaluation of Anti-metastatic Efficacy. Compound 9f
was assessed in a LOX-driven genetically engineered mouse
model (GEMM) of breast cancer that metastasizes to the
lungs.19 Mice were dosed daily by oral gavage (70 mg/kg)
from day 60 when primary tumors start to be palpable (Figure
3). The metastatic nodules in the lungs are measured when the
primary tumors reach an ethical size limit. Pleasingly,
compound 9f reduces lung metastasis significantly, as
measured by the total surface area (Figure 3B).
■ SYNTHETIC CHEMISTRY
AMT-Sulfonamides. All sulfonamide analogues were
synthesized from the sulfonyl chloride intermediates 11a and
11b by condensation with the corresponding amines in
dichloromethane (DCM) (Scheme 1). Subsequent trifluor-
oacetamide hydrolysis or methanolysis using aqueous NaOH
or 7 N NH3 in methanol furnishes the desired amines 2a−2i.
3-Methylthiophene sulfonamide 5f (Table 4) was also
synthesized by this method. Sulfonyl chlorides 11a and 11b
were derived from the commercially available thiophen-2-
ylmethanamines 10a/10b in straightforward steps. Access to
sulfonylhomopiperazine analogues with additional functional-
ization at the free amino group could be achieved via the amine
hydrochloride intermediate 12, where N-substituted sulfonyl-
homopiperazines 2k, 2l, and 2m were obtained in three steps.
The unsubstituted sulfonylhomopiperazine 2j was synthesized
from sulfonyl chloride 11a by condensation with N-Boc-
homopiperazine and trifluoroacetamide hydrolysis, followed by
Boc removal.
AMT-Sulfones. Synthesis of 2-pyridinesulfonyl 3c pro-
ceeded by the lithiation of 2-methylthiophene 14 followed by
condensation with aldrithiol-2 to afford the corresponding
sulfide, which underwent S-oxidation with mCPBA to afford
sulfone 15 (Scheme 2). Subsequent methyl bromination was
followed by the displacement of the bromide by sodium azide
to give the resulting alkyl azide, which was catalytically











(μM)a MAO-A MAO-B IC50 (μM)
a
hERG IC50
(μM) A → B B → A
9g 1.1 [0.75, 1.62] 2.0 [1.3, 3.0] >100, >100 49, 59 A: >100, >100 4.6 8.0 17
B: 87, 89
9l 0.76, 0.86 2.2 [1.4, 3.7] >100, >100 >100, 100 A: 33, 33 68 18 25
B: >100, >100
9f 0.90 [0.55, 1.48] 1.5 [0.28, 8.1] >100, >100 48, 90 A: >100, >100 25 8.5 35
B: >100, >100
aReported IC50 values were determined in at least two separate experiments (n ≥ 2). When n = 2, individual IC50 values are shown. When n > 2,
the values are reported as the geometric mean with the error in square brackets expressed as the 95% confidence interval of the geometric mean.
bPapp: permeability coefficient.
Figure 3. Anti-metastatic efficacy of compound 9f in LOX-driven
GEMM model. Animals treated with vehicle (black) or compound 9f
at 70 mg/kg qd (blue). All values are reported as the arithmetic mean
with the error expressed as the standard error of the means. (A)
Number of lung metastasis, vehicle, n = 7; 9f treated, n = 5; (B) Lung
metastasis area in μm2, vehicle, n = 7; 9f treated, n = 5.
Scheme 1. General Synthetic Routes to AMT-Sulfonamide
Analogues 2a−n and 5fa
aReagents and conditions: (a) TFAA, Et3N, DCM, room temperature
(rt); (b) ClSO3H, DCM, −78 °C to rt, then H2O; (c) oxalyl chloride,
dimethylformamide (DMF), DCM, rt; (d) R2NH, Et3N, DCM, rt; (e)
aq. NaOH, MeOH, rt or 7 N NH3 in MeOH, rt; (f) N-Boc-
homopiperazine, Et3N, DCM, rt; (g) 2 M HCl in Et2O, rt; (h) R′-Cl
(EtNCO for 2l), Et3N, DCM, rt.
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hydrogenated to afford the desired 2-pyridinesulfonyl-AMT 3c.
Similarly, ring opening of 1,2-dithiane with lithiated 2-
methylthiophene followed by condensation with iodomethane
afforded the corresponding bis-sulfide, which underwent
subsequent S-oxidation to afford bis-sulfone 16. This
intermediate was subsequently converted to bis-sulfonylbutyl-
AMT 3j by the method described above.
The commercially available 5-bromo-2-thiophenecarboni-
trile 17a (interchangeable with 5-chloro-2-thiophenecarboni-
trile) and 2-bromothiazole-5-carbonitrile 17b served as
valuable building blocks for the AMT-sulfone inhibitors
(Scheme 3). Nucleophilic aromatic substitution with a range
of thiols afforded the corresponding sulfides, which were
oxidized with mCPBA to afford sulfone intermediates 18.
Subsequent nitrile reduction with borane−tetrahydrofuran
complex afforded AMT-sulfones 3a, 3b, 3d, 3f, 3g, 3i, 5b,
8a, 8b, and 9b. For sulfonylaniline 3h, the product from the
initial condensation 19 underwent an additional sulfonamide
formation step. Subsequent mCPBA-mediated oxidation
afforded the usual sulfone intermediate 18, which was
converted to the desired target. Analogues 3e and 5c were
synthesized from carbamates 20, which were derived from
nitriles 17a and 17b, respectively, by condensation with the
corresponding thiols, followed by nitrile reduction and
subsequent Boc protection.
Sulfonamide-substituted phenylsulfonyl-AMT analogues
8c−8e were synthesized from the corresponding thiols 22
(Scheme 4). Hence, condensation of 3- or 4-fluorophenylsul-
fonyl chloride 21 with the desired amines (HNR2) afforded the
corresponding sulfonamides, which were thiolated by treat-
ment with sodium thiomethoxide to afford intermediate thiols
22. The thiols were condensed with 5-chloro-2-thiophene-
carbonitrile to yield sulfides 23. The nitrile group of sulfides 23
was then converted to the corresponding trifluoroacetamide by
nitrile reduction and amide formation. S-oxidation of sulfides
24 and subsequent amine deprotection affords the desired
AMT targets 8c−8e.
The sulfonyl side chains of AMT analogues 8g−8k were
introduced through the nucleophilic substitution of the
chlorine atom on intermediate 26 (Scheme 5), which could
be obtained in straightforward steps using methods previously
described in Scheme 3. Condensation of intermediate 26 with
2-mercaptoethanol or 3-mercaptopropanol followed by sulfide
oxidation led to alkanol intermediates 27. After Boc removal,
these intermediates afforded AMT targets 8g and 8h.
Alternatively, treatment of hydroxyethylsulfone 27 (n = 1)
with methanesulfonyl chloride led to concomitant sulfonyla-
tion and elimination, furnishing vinyl sulfone 28. Addition of
pyrrolidine to vinyl sulfone 28 followed by Boc removal gives
AMT target 8i. Ammonia addition to intermediate 28 provided
the corresponding aminoethyl sulfone, which was treated with
acetic anhydride to afford the corresponding AMT-acetamide
8j after Boc removal. Methoxyethylsulfone 8k was also
obtained by from vinyl sulfone 28 by methoxide addition
followed by Boc removal.
Phenyl sulfide 29, obtained from methods previously
described in Scheme 3, underwent a Friedel−Crafts
sulfonylation to afford the corresponding phenylsulfonyl
(Scheme 6), which was subsequently oxidized to bis-sulfone
30 using mCPBA. Reduction of the nitrile group with borane−
tetrahydrofuran complex afforded the bis-sulfonylphenyl-AMT
analogue 8f.
tert-Butyl-bis-sulfonylphenyl-AMT 9a was synthesized from
1,3-dibromo-5-(tert-butyl)benzene 31 (Scheme 7). tert-Butyl-
lithium-mediated lithium-bromine exchange of dibromide 31
and treatment of the resultant lithium phenylate with dimethyl
disulfide afforded the corresponding methyl sulfide, which was
oxidized to sulfone 32 using mCPBA. This underwent Pd-
catalyzed cross coupling with thiophene-2-thiol to yield the
corresponding thiophene sulfide, which was formylated under
Vilsmeier−Haack conditions to give aldehyde 33. After
Scheme 2. Synthetic Routes to AMT-Sulfone Analogues 3c
and 3ja
aReagents and conditions: (a) nBuLi, tetrahydrofuran (THF), −40
°C, then aldrithiol-2, −40 °C to rt; (b) mCPBA, DCM, rt; (c) NBS,
Bz2O2, 1,2-dichloroethane (DCE), 70 °C; (d) NaN3, DMF, rt; (e)
H2, Pd/C, THF, rt; (f)
nBuLi, THF, −40 °C, then 1,2-dithiane, −40
°C to rt, then MeI, rt.
Scheme 3. Synthetic Routes to AMT-sulfone Analogues 3a,
3b, 3d−3i, 5b, 5c, 8a, 8b, and 9ba
aReagents and conditions: (a) RSH, K2CO3, DMF, heat; (b)
mCPBA, DCM, rt; (c) BH3·THF, THF, rt; (d) MsCl, Et3N, DCM,
rt; (e) Boc2O, Et3N, DCM, rt; (f) 4 M HCl in dioxane, rt.
Scheme 4. Synthetic Route to Sulfonamide-Substituted
Phenylsulfonyl-AMTs 8c−8ea
aReagents and conditions: (a) HNR2, DCM; (b) NaSMe, DMF, 165
°C; (c) 5-chloro-2-thiophene-carbonitrile, K2CO3, DMF, 120−130
°C; (d) BH3·THF, THF, rt; (e) TFAA, Et3N, DCM; (f) mCPBA,
DCM, rt; (g) 7 N NH3 in MeOH, rt.
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reduction of the aldehyde with sodium borohydride and
subsequent sulfide oxidation, the hydroxyl group was
substituted with azide using diphenyl phosphoryl azide
(DPPA) before it was subsequently reduced to the desired
AMT target 9a.
5-Substituted 1,3-bis-sulfonylphenyl-AMTs 9c−9i were
synthesized from aryl bromide 34.19 Hence, Pd-catalyzed
cross coupling of aryl bromide 34 with trimethylsilylacetylene
under Sonogashira conditions afforded the corresponding aryl-
alkyne (Scheme 8), which was subjected to HCl-mediated Boc
deprotection to afford AMT analogue 9c. The Suzuki−
Miyaura coupling with boronic acids gave the corresponding
biaryl products, which underwent Boc removal to furnish the
desired AMT inhibitors 9d−9i.
5-Substituted 1,4-bis-sulfonylphenyl-AMTs 9j−9l were
synthesized from bromofluorobenzene intermediate 36
(Scheme 9), which could be obtained from the commercially
available 5-bromothiophene-2-carbonitrile 17a and 3-bromo-4-
fluorobenzenethiol 35 by methods previously described in
Scheme 3. Selective substitution of the fluorine atom of
Scheme 5. Synthetic Routes to Phenylsulfonyl-AMTs with Sulfonyl Side-Chain Modifications (8g−8k)a
aReagents and conditions: (a) 2-mercaptoethanol or 3-mercaptopropanol, K2CO3, DMF, 50 °C; (b) mCPBA, DCM, rt (45−61% over two steps);
(c) 4 M HCl in dioxane, rt; (d) MsCl, Et3N, DCM, rt (quant.); (e) pyrrolidine, DCM, rt (85% for steps e + c); (f) 7 N NH3 in MeOH, rt; (g)
Ac2O, Et3N, DCM, rt; (h) K2CO3, MeOH, rt.
Scheme 6. Synthetic Route to Bis-sulfonylphenyl-AMT 8fa
aReagents and conditions: (a) PhSO2Cl, FeCl3, neat, 100 °C; (b) mCPBA, DCM, rt (c) BH3·THF, THF, rt.
Scheme 7. Synthetic Route to tert-Butyl-bis-sulfonylphenyl-
AMT 9aa
aReagents and conditions: (a) tBuLi, THF, −78 °C then MeSSMe,
−78 °C to rt; (b) mCPBA, DCM, rt; (c) thiophene-2-thiol,
Pd2(dba)3, xantphos, K2CO3, p-xylene; 140 °C; (d) POCl3, DMF,
50 °C; (e) NaBH4, THF, rt; (f) DPPA, PPh3, diisopropyl
azodicarboxylate, THF, rt; (g) H2, Pd/C, EtOH, rt.
Scheme 8. Synthetic Routes to Substituted Bis-
sulfonylphenyl-AMTs 9c−9ia
aReagents and conditions: (a) Pd(PPh3)4, CuI, Et3N, trimethylsily-
lacetylene, dioxane, rt; (b) 4 M HCl in dioxane, DCM, rt; (c)
Pd(PPh3)4, RB(OR′)2, Cs2CO3, dioxane, 100 °C.
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intermediate 36 with thiomethoxide afforded the correspond-
ing sulfide, which was oxidized to sulfone 37 using mCPBA.
The Suzuki−Miyaura coupling with boronic acids and
subsequent Boc removal furnished the desired AMT inhibitors
9j−9l.
AMT-Sulfide, AMT-Sulfoxide, and Aminomethylene
Modifications. AMT-sulfide 4b and AMT-sulfoxide 4a
(Scheme 10) were derived from intermediate sulfide 29 (see
Scheme 3; R = Ph). Mono S-oxidation of sulfide 29 with 1
equivalent of mCPBA and subsequent nitrile reduction leads to
AMT-sulfoxide 4a. Reduction of intermediate 29 with
borane−tetrahydrofuran complex, followed by Boc protection
affords carbamate 38. Removal of Boc from carbamate 38 led
to AMT-sulfide 4b, whereas N-methylation using sodium
hydride/iodomethane and subsequent oxidation with mCPBA
affords intermediate 39, which was deprotected to afford the
N-methyl AMT analogue 6a. Alternatively, sulfone 6c can be
obtained from the condensation of bromothiophene 17a and
sodium benzenesulfinate in DMF. This intermediate was
converted to the corresponding thiopheneacetimidamide 6d
and thiophenecarboxamide 6e by treatment with indium
trichloride (InCl3) and lithium hexamethyldisilazide
(LiHMDS), respectively.
Condensation of 1-(5-chlorothiophen-2-yl)ethan-1-one 40
with thiophenol afforded the corresponding sulfide (Scheme
11), which was oxidized to sulfone 41 using mCPBA.
Subsequent oxime formation followed by reduction using
zinc powder in trifluoroacetic acid furnished C-methylated
AMT 6b. Sulfide 42 was obtained in straightforward steps by
methods previously illustrated in Scheme 3. Oxidation of
sulfide 42 with mCPBA afforded the corresponding sulfone 43.
This was reduced to the corresponding aldehyde with DIBAL-
H before conversion to oxime 6f by treatment with
hydroxylamine hydrochloride.
AMT- and Aminomethylenefuran-amides. Synthesis of
AMT-amide 4d and aminomethylenefuran-amide 5f were
accomplished via methyl esters 44 (Scheme 12; A = S or
O).20,21 Esters 44 first underwent saponification with aqueous
hydroxide, and the resultant carboxylic acids were then
converted to acid chlorides 45 using oxalyl chloride.
Condensation with benzylamine in dichloromethane followed
by catalytic hydrogenation using 10% Pd/C in tetrahydrofuran
furnished the desired amides 4d and 5e.
Aminomethylene-pyridine, Aminomethylene-1,3-
Thiazole, and Aminomethylene-Imidazole. Aminomethy-
lene-pyridine 5a was obtained from the commercially available
tert-butyl ((6-chloropyridin-3-yl)methyl)carbamate 46. Con-
densation with sodium benzylthiolate afforded the correspond-
ing sulfide 47 (Scheme 13). Sulfide oxidation with mCPBA
and subsequent HCl-mediated Boc removal furnished the
desired target 5a. 2-(Aminomethylene)-1,3-thiazole 5d was
obtained from sulfide intermediate 49 in a similar manner.
Sulfide 49 was synthesized from tert-butyl ((5-bromothiazol-2-
yl)methyl)carbamate22 48 and naphthalene-2-thiol by a Pd-
catalyzed cross-coupling reaction.
Scheme 9. Synthetic Routes to Substituted Bis-
sulfonylphenyl-AMTs 9j−9la
aReagents and conditions: (a) NaSMe, DMF, rt; (b) mCPBA, DCM,
rt; (c) Pd(PPh3)4, RB(OR′)2, Cs2CO3, dioxane, 100 °C; (d) 4 M HCl
in dioxane, DCM, rt.
Scheme 10. Synthetic Routes to Compounds 4a, 4b, 6a, 6c−6ea
aReagents and conditions: (a) mCPBA (2 equiv), DCM, rt; (b) mCPBA (1 equiv), DCM, rt; (c) BH3·THF, THF, rt; (d) InCl3, acetaldoxime,
toluene, reflux; (e) LiHMDS, Et2O, rt, then 2 M HCl, rt; (f) Boc2O, Et3N, DCM, rt; (g) NaH, MeI, THF, rt; (h) 4 M HCl in dioxane, DCM, rt; (i)
sodium benzenesulfinate, DMF, 135 °C.
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AMT-Sulfone Regiosiomers. The AMT regioisomers 7a−
7c were synthesized by two different methods (Scheme 14).
The synthesis of 2,3-regioisomer 7a began with nucleophilic
aromatic substitution between 3-bromothiophene-2-carbon-
itrile 51 and naphthalene-2-thiol. The resultant sulfide
underwent subsequent sulfide oxidation followed by nitrile
reduction to afford the desired target 7a. The initial
nucleophilic aromatic substitution step was replaced with a
Pd-catalyzed cross coupling for the synthesis of the 3,4- and
2,4-regioisomers 7b and 7c, starting from bromothiophenes 53
and 55. The resultant sulfides were oxidized to sulfones 54 and
56, which were subsequently converted to the corresponding
AMT targets 7b and 7c by nitrile reduction.
Finally, the Suzuki−Miyaura coupling between 5-bromo-
thiophene-2-carbonitrile 17a and (4-(methylthio)phenyl)-
boronic acid 57 affords phenyl thiophene 58 (Scheme 15).
This was converted to carbamate 59 by nitrile reduction, Boc
protection, and sulfide oxidation. Subsequent Boc removal
furnished the phenyl-linked AMT analogue 4e.
Scheme 11. Synthetic Routes to Compounds 6b and 6fa
aReagents and conditions: (a) thiophenol, K2CO3, DMF, 120 °C; (b) mCPBA, DCM, rt; (c) H2NOH·HCl, N,N-diisopropylethylamine (DIPEA),
EtOH, rt; (d) Zn, TFA, rt; (e) DIBAL-H, DCM, 45 °C; (f) H2NOH·HCl, K2CO3, EtOH, 70 °C.
Scheme 12. Synthetic Routes to Amide Analogues 4d and 5ea
aReagents and conditions: (a) 1 M NaOH, MeOH, rt; (b) (COCl)2, DMF, DCM, rt; (c) benzylamine, DCM, rt; (d) H2, Pd/C, THF, rt.
Scheme 13. Synthetic Routes to Aminomethylene-Pyridine, Aminomethylene-Thiazole, and Aminomethylene-Imidazole 5a
and 5da
aReagents and conditions: (a) NaH, benzylmercaptan, DMF, 70 °C; (b) mCPBA, DCM, rt; (c) 2 M HCl in Et2O or 4 M HCl in dioxane, rt; (d)
Pd2(dba)3, xantphos, naphthalene-2-thiol, NaO
tBu, tBuOH/toluene, 100 °C.
Scheme 14. Synthetic Routes to AMT Regioisomers 7a−7ca
aReagents and conditions: (a) naphthalene-2-thiol, K2CO3, DMF,
120 °C; (b) mCPBA, DCM, rt; (c) BH3·THF, THF, rt; (d) Pd2dba3,
xantphos, naphthalene-2-thiol, NaOtBu, toluene, 110 °C.
Scheme 15. Synthetic Route to Phenyl-Linked AMT 4ea
aReagents and conditions: (a) Pd(PPh3)4, Cs2CO3, 1,4-dioxane, 100
°C; (b) BH3·THF, THF, rt; (c) Boc2O, Et3N, DCM, rt; (d) mCPBA,
DCM, rt; (e) 4 M HCl in dioxane, DCM, rt.
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■ CONCLUSIONS
We described herein a series of LOX inhibitors containing a 2-
aminomethylene-5-sulfonyl-thiophene core. The attachment of
a sulfonylphenyl side chain to the core scaffold via the 5-
sulfonyl linker furnishes inhibitors with sub-micromolar LOX
IC50 values. Further SAR optimization leads to the discovery of
inhibitor 9f with potent anti-LOX activity as well as desirable
selectivity and PK profile, making it a valuable asset for LOX
research. More importantly, we have described its ability to
reduce the growth of spontaneous breast tumor lung metastasis
in a GEMM,19 thus demonstrating the promise of 9f as a drug
candidate.
■ EXPERIMENTAL SECTION
Synthesis of Inhibitors. Commercial building blocks, reagents,
and solvents for reactions were reagent grade and used as purchased.
Flash chromatography was performed on a Biotage Isolera flash
purification system using prepacked silica gel cartridges (Biotage)
with HPLC grade solvents. Thin-layer chromatography analysis was
performed using silica gel 60 F-254 thin-layer plates. Liquid
chromatography mass spectrometry (LCMS) and high-resolution
mass spectrometry (HRMS) analyses of chemical compounds were
performed on an Agilent 1200 series HPLC and a diode array
detector coupled to a 6210 time-of-flight mass spectrometer with a
multimode ESI source or a Waters Acquity UPLC and diode array
detector coupled to a Waters G2 QToF mass spectrometer fitted with
a multimode ESI/APCI source. 1H and 13C NMR spectra were
recorded on a Bruker Avance 500 MHz or a 300 MHz spectrometer
using an internal deuterium lock. NMR data is given as follows:
chemical shift (δ) in ppm, multiplicity, coupling constants (J) given in
hertz and integration. All final inhibitors submitted for biological
evaluation were at least 95% pure by HPLC, apart from compound
2g, which has a purity of 94%.
General Procedures GP1. Alkylamine was added to a solution of
sulfonyl chloride 11a in DCM, and the reaction mixture was stirred at
rt for 1−16 h. One molar HCl was added, and the aqueous phase was
extracted with DCM (3×). The combined organic layer was dried
over MgSO4 and filtered, and the solvent was removed under reduced
pressure. MeOH and aq. NaOH were then added, and the mixture
was stirred at rt for 16 h (MeOH and aq. NaOH can be replaced by 7
N NH3 in MeOH). H2O was added, and the aqueous phase was
extracted with DCM (3×). The combined organic phase was dried
over MgSO4 and filtered, and the solvent was removed under reduced
pressure to afford the desired AMT-sulfonamide, which could be
further purified if necessary.
General Procedures GP2. Four molar HCl in dioxane or 2 M HCl
in Et2O was added to tert-butyl carbamate (neat or as a solution in
DCM), and the mixture was stirred at rt for 1−16 h. EtOAc was
added to precipitate the solids if necessary. The solids were collected
by filtration or centrifugation, washed with EtOAc, and dried under
vacuum to afford the desired amine hydrochloride. If necessary, this
can be further purified by chromatography in its free amine form,
which can be obtained by treatment with 7 N NH3 in MeOH.
General Procedures GP3. BH3·THF was added to a solution of
heteroaryl nitrile in THF, and the mixture was stirred at rt for 1−5 h.
EtOH (equal volume to reaction mixture) was then carefully added to
quench the reaction. The solution was subsequently heated at 70 °C
for 1 h to aid borane decomplexation. The solvent was removed under
reduced pressure to afford the desired amine, which could be purified
if necessary.
General Procedures GP4. A mixture of 5-bromothiophene-2-
carbonitrile 17a (interchangeable with 5-chorothiophene-2-carbon-
itrile) or 2-bromothiazole-5-carbonitrile 17b, alkyl or aryl thiol,
K2CO3, and DMF was stirred at 50−140 °C. After cooling to rt, the
mixture was diluted with EtOAc. The organic phase was washed with
1:1 H2O/brine (3×), dried over MgSO4, and filtered. The solvent was
removed under reduced pressure to afford the desired sulfide product,
which could be further purified if necessary.
General Procedures GP5. mCPBA (>2 equiv for sulfones, 1.0
equiv for sulfoxides) was added in small portions to a solution of
sulfide in DCM at 0 °C, and the mixture was stirred at rt (0 °C for
sulfoxides) for 3−16 h. When complete conversion was achieved,
EtOAc was added. The organic phase was washed with sat. NaHCO3
(3×) and sat. Na2S2O3 (until no color was detected on starch iodide
paper), dried over MgSO4, and filtered. The solvent was removed
under reduced pressure to afford the desired sulfone/sulfoxide, which
could be further purified if necessary.
General Procedures GP6. The alkylamine was dissolved in DCM.
Et3N followed by Boc2O were added, and the mixture was stirred at rt
for 16 h. When complete conversion was achieved, DCM was added.
The organic phase was washed with H2O and brine, dried over
MgSO4, and filtered. The solvent was removed under reduced
pressure to afford the desired tert-butyl-carbamate, which could be
further purified if necessary.
General Procedures GP7. A mixture of aryl bromide, Pd(PPh3)4,
ArB(OR′)2 (boronic acid or pinacolatoboronate), Cs2CO3, and 1,4-
dioxane was degassed with argon and then stirred at 100 °C for 16 h.
After cooling to rt, the mixture was filtered through celite and washed
with EtOAc. The solvent was removed under reduced pressure to
afford the desired biaryl, which could be further purified if necessary.
General Procedures GP8. A mixture of aryl bromide, Pd2(dba)3,
Xantphos, alkyl or aryl thiol, NaOtBu, and tBuOH/toluene (1:4) was
degassed with argon and then stirred at 100 °C for 16 h. After cooling
to rt, the suspension was filtered through celite and washed with
DCM. The solvent was removed under reduced pressure to afford the
desired sulfide, which could be further purified if necessary.
(5-(Piperidin-1-ylsulfonyl)thiophen-2-yl)methanamine (2a).
The titled compound was synthesized according to general procedure
GP1, from (i) sulfonyl chloride 11a (150 mg, 0.487 mmol),
piperidine (96.3 μL, 0.975 mmol), and DCM (2.4 mL), 16 h, rt
and (ii) 1 M NaOH (2 mL) and MeOH (2 mL), rt, 16 h. Compound
2a was obtained as a white crystalline solid (109 mg, 86%) and did
not require further purification. 1H NMR (500 MHz, chloroform-d) δ
7.37 (d, J = 3.6 Hz, 1H), 6.92 (d, J = 3.6 Hz, 1H), 4.20 (br, 2H),
3.11−2.96 (m, 4H), 1.82−1.12 (m, 8H). 13C NMR (126 MHz,
chloroform-d) δ 134.51, 132.45, 123.57, 47.10, 25.23, 23.58. HRMS
(ESI) for C10H17N2O2S2 ([M + H]
+): calculated 261.0726; observed
261.0743; error = 4.8 ppm.
5-(Aminomethyl)-N,N-dimethylthiophene-2-sulfonamide
(2b). The titled compound was synthesized according to general
procedure GP1, from (i) sulfonyl chloride 11a (100 mg, 0.325
mmol), dimethylamine (40% in H2O; 0.206 mL, 1.62 mmol), and
DCM (1.63 mL), 16 h, rt and (ii) 30% NaOH (0.5 mL) and MeOH
(3 mL), rt, 16 h. Compound 2b was obtained as a white solid (38 mg,
53%) and did not require further purification. 1H NMR (500 MHz,
chloroform-d) δ 7.41 (d, J = 3.7 Hz, 1H), 6.95 (dt, J = 3.7, 1.0 Hz,
1H), 4.12 (d, J = 0.6 Hz, 2H), 2.76 (s, 6H), 1.61 (s, 2H). 13C NMR
(126 MHz, chloroform-d) δ 155.65, 133.60, 132.76, 123.60, 41.66,
38.18. HRMS (ESI) for C7H13N2O2S2 ([M + H]
+): calculated
221.0413; observed 221.0409; error = 1.8 ppm.
5-(Aminomethyl)-N-ethylthiophene-2-sulfonamide (2c).
The titled compound was synthesized according to general procedure
GP1, from (i) sulfonyl chloride 11a (100 mg, 0.325 mmol),
ethylamine (2.0 M in MeOH; 0.812 mL, 1.62 mmol), and DCM
(1.63 mL), 16 h, rt and (ii) 30% NaOH (0.5 mL) and MeOH (3
mL), rt, 16 h. Compound 2c was obtained as a colorless oil (23 mg,
32%) and did not require further purification. 1H NMR (500 MHz,
chloroform-d) δ 7.46 (d, J = 3.7 Hz, 1H), 6.88 (d, J = 3.7 Hz, 1H),
4.68 (br, 1H), 4.09 (s, 2H), 3.09 (q, J = 7.2 Hz, 2H), 1.76 (br, 2H),
1.15 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, chloroform-d) δ
155.38, 138.81, 132.43, 123.47, 41.60, 38.62, 15.11. HRMS (ESI) for
C7H10NO2S2 ([M − NH2]+): calculated 204.1480; observed
204.01460; error = 0.98 ppm.
(S)-1-(5-(Aminomethyl)thiophen-2-ylsulfonyl)pyrrolidine-2-
carboxamide (2d). The titled compound was synthesized according
to general procedure GP1, from (i) sulfonyl chloride 11a (75 mg,
0.244 mmol), prolinamide hydrochloride (30.6 mg, 0.268 mmol),
Et3N (74.7 μL, 0.536 mmol), and DCM (1.2 mL), 16 h, rt and (ii) 1
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M NaOH (1.2 mL) and MeOH (1.2 mL), rt, 16 h. The crude was
purified by chromatography (1 N NH3 in MeOH/DCM 0→ 20%) to
afford an orange oil (10 mg, 14%). [α]D
21 −134.2 (c 0.16, MeOH/
CHCl3).
1H NMR (500 MHz, methanol-d4) δ 7.58 (d, J = 3.8 Hz,
1H), 7.15 (d, J = 3.8 Hz, 1H), 4.10 (s, 2H), 4.06 (dd, J = 8.3, 4.0 Hz,
1H), 3.61 (ddd, J = 10.2, 6.1, 4.6 Hz, 1H), 3.32 (m, 1H), 1.99 (m,
1H), 1.93−1.82 (m, 2H), 1.67 (m, 1H). 13C NMR (126 MHz,
methanol-d4) δ 177.35, 154.70, 135.83, 134.45, 126.75, 63.79, 50.93,
41.12, 32.07, 25.51. HRMS (ESI) for C10H13N2O3S2 ([M − NH2]+):
calculated 273.0362; observed 273.0334; error = 10 ppm.
(S)-(1-(5-(Aminomethyl)thiophen-2-ylsulfonyl)pyrrolidin-2-
yl)methanol (2e). The titled compound was synthesized according
to general procedure GP1, from (i) sulfonyl chloride 11a (100 mg,
0.325 mmol), (S)-pyrrolidin-2-ylmethanol (35.3 μL, 0.358 mmol),
Et3N (100 μL, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N
NH3 in MeOH (5 mL), rt, 20 h. The crude was purified by
chromatography (1 N NH3 in MeOH/DCM 0 → 15%) to afford a
yellow oil (47 mg, 52%). [α]D
21 −33.6 (c 2.76, MeOH/CHCl3). 1H
NMR (500 MHz, chloroform-d) δ 7.47 (d, J = 3.8 Hz, 1H), 6.94 (dt, J
= 3.7, 1.0 Hz, 1H), 4.11 (d, J = 0.8 Hz, 2H), 3.80−3.57 (m, 3H),
3.53−3.45 (m, 1H), 3.30 (dt, J = 10.5, 7.1 Hz, 1H), 2.18−1.95 (m,
3H), 1.90−1.69 (m, 3H), 1.60−1.50 (m, 1H). 13C NMR (126 MHz,
chloroform-d) δ 155.82, 134.49, 133.01, 123.57, 65.67, 62.29, 50.22,
41.55, 28.90, 24.41. HRMS (ESI) for C10H17N2O3S2 ([M + H]
+):
calculated 277.0675; observed 277.0629; error = 17 ppm.
(5-(2-Phenylpyrrolidin-1-ylsulfonyl)thiophen-2-yl)-
methanamine (2f). The titled compound was synthesized according
to general procedure GP1, from (i) sulfonyl chloride 11a (100 mg,
0.325 mmol), 2-phenylpyrrolidine (40.7 mg, 0.357 mmol), Et3N (100
μL, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N NH3 in
MeOH (4 mL), rt, 16 h. The crude was purified by chromatography
(1 N NH3 in MeOH/DCM 0 → 20%) to afford a brown oil (40 mg,
38%). 1H NMR (500 MHz, chloroform-d) δ 7.42 (d, J = 3.7 Hz, 1H),
7.38−7.21 (m, 5H), 6.90 (dt, J = 3.7, 1.0 Hz, 1H), 4.80 (dd, J = 8.0,
3.6 Hz, 1H), 4.10 (d, J = 0.9 Hz, 2H), 3.68 (m, 1H), 3.45 (dt, J =
10.5, 7.3 Hz, 1H), 2.04 (m, 1H), 1.96−1.81 (m, 2H), 1.70 (m, 1H),
1.53 (s, 2H). 13C NMR (126 MHz, chloroform-d) δ 155.35, 143.01,
135.67, 132.68, 128.44, 127.18, 126.22, 123.38, 63.71, 49.77, 41.57,
35.82, 24.08. HRMS (ESI) for C15H19N2O2S2 ([M + H]
+): calculated
323.0883; observed 323.0873; error = 3.1 ppm.
(5-(Indolin-1-ylsulfonyl)thiophen-2-yl)methanamine (2g).
The titled compound was synthesized according to general procedure
GP1, from (i) sulfonyl chloride 11a (100 mg, 0.325 mmol), indoline
(142 mg, 0.358 mmol), Et3N (100 μL, 0.715 mmol), and DCM (1.6
mL), 2 h, rt and (ii) 7 N NH3 in MeOH (5 mL) at rt, for 20 h. The
crude was purified by chromatography (1 N NH3 in MeOH/DCM 0
→ 15%) to afford a brown solid (73 mg, 76%). 1H NMR (500 MHz,
chloroform-d) δ 7.58 (d, J = 8.1 Hz, 1H), 7.42 (d, J = 3.8 Hz, 1H),
7.24−7.16 (m, 1H), 7.12 (d, J = 7.4 Hz, 1H), 7.00 (td, J = 7.4, 0.9 Hz,
1H), 6.88−6.78 (m, 1H), 4.01 (s, 2H), 3.95 (d, J = 8.4 Hz, 2H), 2.98
(t, J = 8.4 Hz, 2H), 1.56 (s, 2H). 13C NMR (126 MHz, chloroform-d)
δ 156.23, 141.59, 133.90, 132.97, 131.84, 127.81, 125.24, 124.07,
123.43, 115.10, 50.30, 50.25, 41.51, 27.91. HRMS (ESI) for
C13H15N2O2S2 ([M + H]
+): calculated 295.0569; observed
295.0577; error = 2.7 ppm.
(5-(3,4-Dihydroquinolin-1(2H)-ylsulfonyl)thiophen-2-yl)-
methanamine (2h). The titled compound was synthesized
according to general procedure GP1, from (i) sulfonyl chloride 11a
(100 mg, 0.325 mmol), tetrahydroquinoline (44.9 μL, 0.357 mmol),
Et3N (100 μL, 0.715 mmol), and DCM (1.6 mL), 2 h, rt and (ii) 7 N
NH3 in MeOH (5 mL), rt, 20 h. The crude was purified by
chromatography (1 N NH3 in MeOH/DCM 0 → 10%) to afford a
brown foam (27 mg, 27%). 1H NMR (500 MHz, chloroform-d) δ
7.78 (d, J = 8.3 Hz, 1H), 7.25−7.16 (m, 2H), 7.13−7.02 (m, 2H),
6.84 (d, J = 3.7 Hz, 1H), 4.04 (s, 2H), 3.87−3.81 (m, 2H), 2.54 (t, J =
6.7 Hz, 2H), 2.37−1.82 (m, 2H), 1.80−1.72 (br, 2H). 13C NMR (126
MHz, chloroform-d) δ 137.52, 136.43, 132.42, 130.96, 129.27,
126.69, 125.28, 125.03, 123.78, 46.98, 41.34, 26.93, 21.78. HRMS
(ESI) for C14H17N2O2S2 ([M + H]
+): calculated 309.0726; observed
309.0732; error = 1.9 ppm.
(5-(Morpholinosulfonyl)thiophen-2-yl)methanamine (2i).
The titled compound was synthesized according to general procedure
GP1, from (i) sulfonyl chloride 11a (75 mg, 0.244 mmol),
morpholine (42.7 μL, 0.487 mmol), and DCM (1.2 mL), 16 h, rt
and (ii) 1 M NaOH (1 mL) and MeOH (1 mL), rt, 16 h. The crude
was dissolved in MeOH, passed through an SCX ion exchange
(sulfonic acid) column, and washed with MeOH. The amine was
released by the addition of 1 N NH3 in MeOH to afford a crystalline
solid (47 mg, 73%). 1H NMR (500 MHz, chloroform-d) δ 7.40 (d, J =
3.7 Hz, 1H), 6.95 (d, J = 3.6 Hz, 1H), 4.08 (br, 2H), 3.90−3.65 (m,
4H), 3.15−2.89 (m, 4H), 1.64 (br, 2H). 13C NMR (126 MHz,
chloroform-d) δ 133.16, 133.01, 123.70, 66.13, 46.12. HRMS (ESI)
for C9H15N2O3S2 ([M + H]
+): calculated 263.0519; observed
263.0533; error = 5.3 ppm.
(5-(1,4-Diazepan-1-ylsulfonyl)thiophen-2-yl)methanamine
Dihydrochloride (2j). tert-Butyl 4-((5-(aminomethyl)thiophen-2-
yl)sulfonyl)-1,4-diazepane-1-carboxylate was synthesized according to
general procedure GP1, from (i) sulfonyl chloride 11a (75 mg, 0.244
mmol), N-Boc-homopiperazine (53.7 mg, 0.268 mmol), Et3N (74.7
μL, 0.536 mmol), and DCM (1.2 mL), rt, 16 h and (ii) 1 M NaOH (5
mL), MeOH (5 mL), rt, 16 h. The crude was used in the subsequent
transformation immediately.
Compound 2j was synthesized according to general procedure
GP2, from tert-butyl 4-((5-(aminomethyl)thiophen-2-yl)sulfonyl)-
1,4-diazepane-1-carboxylate (crude) and 2 M HCl in Et2O (10
mL), rt, 16. Compound 2j was obtained as a pink solid (43 mg, 63%).
1H NMR (500 MHz, D2O) δ 7.77 (br, 1H), 7.44 (br, 1H), 4.55 (s,
2H), 3.75 (br, 2H), 3.60−3.45 (m, 6H), 2.23 (br, 2H). 13C NMR
(126 MHz, D2O) δ 141.90, 137.80, 133.32, 130.36, 47.20, 46.84,
44.85, 44.38, 37.31, 25.22. HRMS (ESI) for C10H18N3O2S2 ([M +
H]+): calculated 276.0835; observed 276.0771; error = 23 ppm.
(5-(4-Methyl-1,4-diazepan-1-ylsulfonyl)thiophen-2-yl)-
methanamine (2k). A mixture of sulfonyl chloride 11a (645 mg,
2.10 mmol), N-Boc-homopiperazine (449 μL, 2.31 mmol), Et3N (643
μL, 4.61 mmol), and DCM (10 mL) was stirred at rt for 2 h. One
molar HCl (30 mL) was added. The aqueous phase was extracted
with DCM (3 × 15 mL). The combined organic phase was dried over
MgSO4 and filtered, and the solvent was removed under reduced
pressure. The intermediate was dissolved in 2 M HCl in Et2O (10
mL), and the mixture was stirred at rt for 16 h. The solids were
collected, washed with Et2O, and dried under vacuum to afford N-((5-
((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroa-
cetamide hydrochloride as a beige solid (580 mg, 68%). 1H NMR
(500 MHz, D2O) δ 7.70 (m, 1H), 7.27 (m, 1H), 3.74−3.70 (m, 2H),
3.56−3.42 (m, 6H), 2.27−2.13 (m, 2H). HRMS (ESI) for
C12H17F3N3O3S2 ([M + H]
+): calculated 372.0658.
A mixture of N-((5-((1,4-diazepan-1-yl)sulfonyl)thiophen-2-yl)-
methyl)-2,2,2-trifluoroacetamide hydrochloride (80 mg, 0.196 mmol),
MeI (18.0 μL, 0.294 mmol), Et3N (68.0 μL, 0.490 mmol), and DCM
(1.0 mL) was stirred at rt for 48 h. H2O (10 mL) was added. The
aqueous phase was extracted with DCM (3 × 10 mL). The combined
organic phase was removed under reduced pressure. The intermediate
was dissolved in 7 N NH3 in MeOH (3 mL), and the mixture was
stirred at rt for 24 h. The solvent was removed under reduced
pressure, and the crude was purified by chromatography (1 N NH3 in
MeOH/DCM 0 → 20%) to afford compound 2k as a brown oil (12
mg, 21%). 1H NMR (500 MHz, chloroform-d) δ 7.40 (d, J = 3.7 Hz,
1H), 6.89 (dt, J = 3.7, 0.9 Hz, 1H), 4.10 (d, J = 0.8 Hz, 2H), 3.45−
3.38 (m, 4H), 2.69−2.61 (m, 4H), 2.36 (s, 2H), 1.88 (dt, J = 11.7, 6.2
Hz, 2H), 1.69 (s, 3H). 13C NMR (126 MHz, chloroform-d) δ 155.05,
137.16, 131.90, 123.37, 58.55, 56.84, 48.04, 47.38, 46.58, 41.66, 27.55.
HRMS (ESI) for C11H20N3O2S2 ([M + H]
+): calculated 290.0992;
observed 290.0861; error = 45 ppm.
4-(5-(Aminomethyl)thiophen-2-ylsulfonyl)-N-ethyl-1,4-dia-
zepane-1-carboxamide (2l). A mixture of N-((5-((1,4-diazepan-1-
yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydro-
chloride (80 mg, 0.196 mmol), EtNCO (17.0 μL, 0.216 mmol),
Et3N (54.7 μL, 0.392 mmol), and DCM (1.0 mL) was stirred at rt for
2 h. DCM (10 mL) was added. The organic phase was washed with
H2O and brine (10 mL each), dried over MgSO4, and filtered, and the
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solvent was removed under reduced pressure. The intermediate was
dissolved in 7 N NH3 in MeOH (3 mL), and the mixture was stirred
at rt for 16 h. The solvent was removed under reduced pressure, and
the crude was purified by chromatography (MeOH/DCM 0 → 20%)
to afford compound 2l as a colorless oil (60 mg, 88%). 1H NMR (500
MHz, chloroform-d) δ 7.38 (d, J = 3.7 Hz, 1H), 6.88 (dt, J = 3.7, 0.9
Hz, 1H), 4.39 (s, 1H), 4.08 (s, 2H), 3.62−3.57 (m, 2H), 3.49 (t, J =
6.4 Hz, 2H), 3.36−3.32 (m, 2H), 3.29−3.20 (m, 4H), 2.02−1.94 (m,
2H), 1.69 (s, 2H), 1.11 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz,
chloroform-d) δ 157.38, 155.48, 136.96, 132.01, 123.40, 50.69, 48.51,
48.13, 45.28, 41.58, 35.79, 28.24, 15.70. HRMS (ESI) for
C13H23N4O3S2 ([M + H]
+): calculated 347.1206; observed
347.1196; error = 2.9 ppm.
(5-(4-(Methylsulfonyl)-1,4-diazepan-1-ylsulfonyl)thiophen-
2-yl)methanamine (2m). A mixture of N-((5-((1,4-diazepan-1-
yl)sulfonyl)thiophen-2-yl)methyl)-2,2,2-trifluoroacetamide hydro-
chloride (80 mg, 0.196 mmol), MsCl (16.7 μL, 0.216 mmol), Et3N
(68.0 μL, 0.490 mmol), and DCM (1.0 mL) was stirred at rt for 48 h·
H2O (10 mL) was added. The aqueous phase was extracted with
DCM (3 × 10 mL). The combined organic phase was dried over
MgSO4 and filtered, and the solvent was removed under reduced
pressure. The intermediate was dissolved in 7 N NH3 in MeOH (3
mL), and the mixture was stirred at rt for 24 h. The solvent was
removed under reduced pressure, and the crude was purified by
chromatography (1 N NH3 in MeOH/DCM 0 → 20%) to afford
compound 2m as a white solid (44 mg, 63%). 1H NMR (500 MHz,
chloroform-d) δ 7.39 (d, J = 3.8 Hz, 1H), 6.88 (dt, J = 3.7, 1.0 Hz,
1H), 4.08 (d, J = 0.9 Hz, 2H), 3.54−3.34 (m, 8H), 2.85 (s, 3H), 2.00
(pentet, J = 6.3 Hz, 2H), 1.62 (s, 2H). 13C NMR (126 MHz,
chloroform-d) δ 155.81, 136.76, 132.10, 123.37, 51.25, 50.49, 47.76,
47.27, 41.56, 38.13, 29.33. HRMS (ESI) for C11H20N3O4S3 ([M +
H]+): calculated 354.0611; observed 354.0530; error = 23 ppm.
(5-(Cyclohexylsulfonyl)thiophen-2-yl)methanamine (3a).
NaH (60% in mineral oil; 39.6 mg, 0.985 mmol) was added to a
solution of 5-bromothiophene-2-carbonitrile 17a (100 μL, 0.901
mmol) and cyclohexylmercaptan (121 μL, 0.991 mmol) in DMF (3.0
mL), and the mixture was stirred at 130 °C for 16 h. After cooling to
rt, EtOAc (15 mL) was added. The organic phase was washed with
1:1 H2O/brine (3 × 15 mL), dried over MgSO4, and filtered. The
solvent was removed under reduced pressure, and the intermediate
was dissolved in DCM (3.0 mL). mCPBA (77%; 489 mg, 2.18 mmol)
was added in small portions, and the mixture was stirred at rt for 3 h.
DCM (15 mL) was added. The organic phase was washed with 1 M
NaOH (3 × 15 mL) and brine (15 mL), dried over MgSO4, and
filtered. The solvent was removed under reduced pressure, and the
crude was purified by chromatography (EtOAc/cyclohexane 0 →
20%) to afford 5-(cyclohexylsulfonyl)thiophene-2-carbonitrile as a
white crystalline solid (50 mg, 22%). 1H NMR (500 MHz,
chloroform-d) δ 7.65 (d, J = 4.0 Hz, 1H), 7.61 (d, J = 4.0 Hz,
1H), 3.03 (tt, J = 12.1, 3.4 Hz, 1H), 2.19−2.11 (m, 2H), 1.97−1.88
(m, 2H), 1.72 (m, 1H), 1.65−1.10 (m, 5H). LCMS (ESI) m/z 278
[M + Na]+.
Compound 3a was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 0.58 mL, 0.58 mmol), 5-
(cyclohexylsulfonyl)thiophene-2-carbonitrile (49 mg, 0.192 mmol),
and THF (1.9 mL), rt, 1 h. The crude was purified by
chromatography (MeOH/DCM 0 → 15%) to afford a white solid
(12 mg, 24%). 1H NMR (500 MHz, chloroform-d) δ 7.50 (d, J = 3.8
Hz, 1H), 6.96 (m, 1H), 4.12 (s, 2H), 2.95 (tt, J = 12.1, 3.4 Hz, 1H),
2.20−2.12 (m, 2H), 1.92−1.84 (m, 2H), 1.68 (d, J = 21.7 Hz, 3H),
1.51−1.38 (m, 2H), 1.33−1.08 (m, 3H). 13C NMR (126 MHz,
chloroform-d) δ 158.07, 135.80, 135.11, 123.83, 64.77, 41.72, 25.97,
25.27, 25.19. HRMS (ESI) for C11H17 NO2S2 ([M + H]
+): calculated
260.0773; observed 260.0785; error = 4.6 ppm.
(5-(Phenylsulfonyl)thiophen-2-yl)methanamine (3b). A mix-
ture of nitrile 6c (39 mg, 0.156 mmol), LiAlH4 (1.0 M in THF; 160
μL, 0.160 mmol), and THF (1.6 mL) was stirred at 0 °C for 1 h. H2O
(5 mL) was slowly added, and the aqueous phase was extracted with
DCM (3 × 8 mL). The combined organic phase was washed with
brine (10 mL), dried over MgSO4, and filtered. The solvent was
removed under reduced pressure, and the crude was purified by
chromatography (7 N NH3 in MeOH/DCM 0 → 60%) to afford
compound 3b as a light brown crystalline solid (15 mg, 38%). 1H
NMR (500 MHz, chloroform-d) δ 8.01−7.95 (m, 2H), 7.63−7.48
(m, 4H), 6.88 (dt, J = 3.8, 1.0 Hz, 1H), 4.07 (s, 2H), 1.58 (s, 2H).
13C NMR (126 MHz, chloroform-d) δ 158.19, 142.50, 140.63,
133.70, 133.26, 129.39, 127.41, 123.80, 41.71. HRMS (ESI) for
C11H12NO2S2 ([M + H]
+): calculated 254.0304; observed 254.0309;
error = 2.0 ppm.
(5-(Pyridin-2-ylsulfonyl)thiophen-2-yl)methanamine (3c). A
mixture of 2-((5-methylthiophen-2-yl)sulfonyl)pyridine 15 (310 mg,
1.30 mmol), Bz2O2 (75%; 20.9 mg, 0.0648 mmol), NBS (253 mg,
1.42 mmol), and DCE (6.5 mL) was stirred at 80 °C for 16 h. The
solvent was removed under reduced pressure, and the crude was
purified by chromatography (EtOAc/cyclohexane 20 → 40%) to
afford 2-((5-(bromomethyl)thiophen-2-yl)sulfonyl)pyridine as a
white solid (294 mg, 71%). 1H NMR (500 MHz, chloroform-d) δ
8.74 (s, 1H), 8.19 (s, 1H), 7.97 (s, 1H), 7.71 (s, 1H), 7.53 (s, 1H),
7.13 (d, J = 3.9 Hz, 1H), 4.66 (s, 2H). LCMS (ESI) m/z 318/320 [M
+ H]+.
A mixture of 2-((5-(bromomethyl)thiophen-2-yl)sulfonyl)pyridine
(133 mg, 0.418 mmol), NaN3 (32.6 mg, 0.502 mmol), and DMF (2.1
mL) was stirred at 70 °C for 16 h. After cooling to rt, EtOAc (20 mL)
was added. The organic phase was washed with 1:1 H2O/brine (2 ×
20 mL), dried over MgSO4, and filtered. The solvent was removed
under reduced pressure, and the intermediate was dissolved in THF
(2.1 mL), and Pd/C (10%; 44 mg, 0.0418 mmol) was then added.
The mixture was stirred at rt under a H2 atmosphere (balloon) for 16
h and subsequently filtered through celite. The solvent was removed
under reduced pressure, and the crude was purified by chromatog-
raphy (MeOH/DCM 0 → 20%) to afford compound 3c as a white
solid (53 mg, 50%). 1H NMR (500 MHz, chloroform-d) δ 8.69 (ddd,
J = 4.7, 1.7, 0.9 Hz, 1H), 8.15 (dt, J = 7.9, 1.0 Hz, 1H), 7.92 (td, J =
7.8, 1.7 Hz, 1H), 7.70 (d, J = 3.8 Hz, 1H), 7.46 (ddd, J = 7.6, 4.7, 1.1
Hz, 1H), 6.92 (dt, J = 3.9, 1.0 Hz, 1H), 4.07 (d, J = 0.9 Hz, 2H), 1.62
(s, 2H). 13C NMR (126 MHz, chloroform-d) δ 159.60, 159.12,
150.48, 138.27, 136.95, 135.65, 127.01, 123.94, 121.78, 41.71. HRMS
(ESI) for C10H11N2O2S2 ([M + H]
+): calculated 255.0257; observed
255.0276; error = 7.5 ppm.
(5-(Thiophen-2-ylsulfonyl)thiophen-2-yl)methanamine Hy-
drochloride (3d). The titled compound was synthesized according
to general procedures GP4, GP5, and GP3, from (i) 5-
bromothiophene-2-carbonitrile 17a (1.0 g, 5.32 mmol), thiophene-
2-thiol (586 mg, 5.05 mmol), K2CO3 (881 mg, 6.38 mmol), and
DMF (17 mL), 80 °C, 16 h; (ii) mCPBA (77%; 1.30 g, 11.2 mmol)
and DCM (36 mL), rt, 3 h; and (iii) BH3 (1.0 M in THF; 10.6 mL,
10.6 mmol) and THF (10.6 mL), rt, 1 h. Chromatography (EtOH/
cyclohexane 0 → 100%) afforded a brown gum (323 mg, 25%). 1H
NMR (500 MHz, chloroform-d) δ 7.64 (dd, J = 5.0, 1.3 Hz, 1H), 7.52
(dd, J = 3.7, 1.3 Hz, 1H), 7.43 (d, J = 3.7 Hz, 1H), 7.11 (dd, J = 5.0,
3.7 Hz, 1H), 6.90 (dt, J = 3.7, 0.9 Hz, 1H), 3.93 (s, 2H), 1.63 (br,
2H). 13C NMR (126 MHz, chloroform-d) δ 155.85, 147.91, 145.56,
131.64, 130.91, 129.86, 127.48, 123.47, 41.84. HRMS (ESI) for
C9H7O2S3 ([M − NH2]+): calculated 242.9608; observed 242.9608;
error = 0 ppm.
(5-(Biphenyl-3-ylsulfonyl)thiophen-2-yl)methanamine Hy-
drochloride (3e). 5-([1,1′-Biphenyl]-3-ylthio)thiophene-2-carbon-
itrile was synthesized according to general procedures GP4, from 5-
bromothiophene-2-carbonitrile 17a (160 mg, 1.11 mmol), [1,1′-
biphenyl]-3-thiol (223 mg, 1.22 mmol), K2CO3 (308 mg, 2.23
mmol), and DMF (4.6 mL), 120 °C, 16 h. Chromatography (EtOAc/
cyclohexane 0→ 20%) afforded a brown oil (327 mg, 92%). 1H NMR
(500 MHz, methanol-d4) δ 7.13−7.80 (m, 11H). LCMS (ESI) m/z
294 [M + H]+.
tert-Butyl ((5-([1,1′-biphenyl]-3-ylthio)thiophen-2-yl)methyl)-
carbamate was synthesized according to general procedures GP3
and GP6, from (i) 5-([1,1′-biphenyl]-3-ylthio)thiophene-2-carbon-
itrile (264 mg, 0.910 mmol), BH3 (1.0 M in THF; 2.7 mL, 2.70
mmol), THF (2.7 mL), rt, 1 h and (ii) Boc2O (590 mg, 2.70 mmol),
Et3N (250 μL, 1.80 mmol), and DCM (3.5 mL), rt, 16 h.
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Chromatography (EtOAc/cyclohexane 0 → 30%) afforded a yellow
oil (64 mg, 18%). 1H NMR (500 MHz, chloroform-d) δ 7.56 (m,
1H), 7.55 (m, 1H), 7.49 (m, 1H), 7.46 (m, 2H), 7.43−7.33 (m, 3H),
7.20 (m, 2H), 6.93 (d, J = 3.3 Hz, 1H), 5.04 (s, 1H), 4.49 (s, 2H),
1.50 (s, 9H). LCMS (ESI) m/z 281 [M − BocNH]+.
Compound 3e was synthesized according to general procedures
GP5 and GP2, from (i) tert-butyl ((5-([1,1′-biphenyl]-3-ylthio)-
thiophen-2-yl)methyl)carbamate (64 mg, 0.161 mmol), mCPBA
(77%; 69 mg, 0.402 mmol), and DCM (2.0 mL), 45 °C, 1.5 h and
(ii) 4 M HCl in dioxane (8.0 mL), rt, 16 h. The white precipitate was
filtered and washed with excess EtOAc to afford a white solid (25 mg,
42% over two steps). 1H NMR (500 MHz, methanol-d4) δ 8.19 (m,
1H), 7.99 (ddd, J = 7.8, 1.8, 1.0 Hz, 1H), 7.96 (ddd, J = 7.8, 1.8, 1.0
Hz, 1H), 7.81 (d, J = 3.9 Hz, 1H), 7.70 (t, J = 7.7 Hz, 1H), 7.65 (m,
2H), 7.52 (m, 2H), 7.44 (m, 1H), 7.32 (d, J = 3.8 Hz, 1H), 4.38 (s,
2H). 13C NMR (126 MHz, chloroform-d) δ 144.2, 143.8, 142.8,
142.4, 138.8, 133.8, 131.9, 130.3, 130.1, 128.9, 128.2, 126.7, 125.7,
125.1, 37.1. HRMS (ESI) for C17H13O2S2 ([M − NH2]+): calculated
313.0357; observed 313.0359; error = 0.64 ppm.
(5-(Naphthalen-1-ylsulfonyl)thiophen-2-yl)methanamine
(3f). 5-(Naphthalen-1-ylsulfonyl)thiophene-2-carbonitrile was synthe-
sized according to general procedures GP4 and GP5, from (i) 5-
chlorothiophene-2-carbonitrile 17a (95 μL, 0.901 mmol), naphtha-
lene-1-thiol (137 μL, 0.991 mmol), K2CO3 (250 mg, 1.80 mmol), and
DMF (3.0 mL), 120 °C, 16 h and (ii) mCPBA (77%; 504 mg, 2.25
mmol) and DCM (15 mL), rt, 16 h. Chromatography (EtOAc/
cyclohexane 0 → 15%) afforded a colorless oil (170 mg, 63%). 1H
NMR (500 MHz, chloroform-d) δ 8.78 (m, 1H), 8.51 (dd, J = 7.4, 1.2
Hz, 1H), 8.17 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.75−
7.67 (m, 2H), 7.67−7.59 (m, 2H), 7.49 (d, J = 4.1 Hz, 1H). LCMS
(ESI) m/z 300 [M + H]+.
Compound 3f was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 1.10 mL, 1.10 mmol), 5-(naphthalen-
1-ylsulfonyl)thiophene-2-carbonitrile (110 mg, 0.367 mmol), and
THF (1.8 mL), rt, 2 h. Chromatography (MeOH/DCM 0 → 20%)
afforded a white crystalline solid (25 mg, 23%). 1H NMR (500 MHz,
chloroform-d) δ 8.86 (dd, J = 8.7, 0.8 Hz, 1H), 8.47 (dd, J = 7.4, 1.2
Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.95−7.87 (m, 1H), 7.70−7.64 (m,
2H), 7.63−7.54 (m, 2H), 6.84 (dt, J = 3.9, 1.0 Hz, 1H), 4.01 (d, J =
0.9 Hz, 2H), 1.58 (s, 3H). 13C NMR (126 MHz, chloroform-d) δ
157.61, 141.08, 137.18, 135.25, 134.40, 133.68, 129.61, 129.23,
128.54, 127.07, 124.65, 124.63, 123.50, 41.67. HRMS (ESI) for
C15H11O2S2 ([M − NH2]+): calculated 287.0195; observed 287.0226;
error = 11 ppm.
(5-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine
(3g). Compound 3g was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 5.10 mL, 5.10 mmol), 5-(naphthalen-
2-ylsulfonyl)thiophene-2-carbonitrile 43 (510 mg, 1.71 mmol) and
THF (10 mL), rt, 3 h. Chromatography (EtOH/cyclohexane 30 →
100%) afforded a white solid (273 mg, 54%). 1H NMR (500 MHz,
chloroform-d) δ 8.58 (s, 1H), 8.01−7.87 (m, 4H), 7.68−7.57 (m,
3H), 6.88 (m, 1H), 4.05 (s, 2H), 1.56 (s, 2H). 13C NMR (126 MHz,
chloroform-d) δ 158.24, 140.73, 139.30, 135.17, 133.73, 132.40,
129.75, 129.59, 129.25, 128.71, 128.06, 127.75, 123.82, 122.58, 41.68.
HRMS (ESI) for C15H11O2S2 ([M − NH2]+): calculated 287.0195;
observed 287.0207; error = 4.2 ppm.
N-(4-(5-(Aminomethyl)thiophen-2-ylsulfonyl)phenyl)-
methanesulfonamide (3h). A mixture of 5-((4-aminophenyl)thio)-
thiophene-2-carbonitrile 19 (120 mg, 0.517 mmol), MsCl (44.0 μL,
0.568 mmol), and pyridine (1.7 mL) was stirred at rt for 16 h. Two
molar HCl (30 mL) was added. The aqueous phase was extracted
with DCM (3 × 20 mL). The combined organic phase was dried over
MgSO4 and filtered. The solvent was removed under reduced
pressure, and the crude was dissolved in DCM (2.6 mL). mCPBA
(77%; 254 mg, 1.14 mmol) was added, and the mixture was stirred at
rt for 5 h. sat. NaHCO3 (40 mL) was added, and the aqueous phase
was extracted with EtOAc (3 × 40 mL). The combined organic phase
was dried over MgSO4 and filtered. The solvent was removed under
reduced pressure, and the crude was purified by chromatography
(MeOH/DCM 0 → 15%) to afford N-(4-((5-cyanothiophen-2-
yl)sulfonyl)phenyl)methanesulfonamide as a white solid (69 mg,
39%). 1H NMR (500 MHz, chloroform-d) δ 7.50 (d, J = 3.9 Hz, 1H),
7.41−7.37 (m, 2H), 7.26−7.19 (m, 3H), 7.09 (d, J = 3.9 Hz, 1H),
3.05 (s, 3H). LCMS (ESI) m/z 365 [M + Na]+.
Compound 3h was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 0.61 mL, 0.61 mmol), N-(4-((5-
cyanothiophen-2-yl)sulfonyl)phenyl)methanesulfonamide (69 mg,
0.202 mmol), and THF (0.6 mL), rt, 1 h. Chromatography
(MeOH/DCM 5 → 25%) afforded a yellow solid (2 mg, 3%). 1H
NMR (500 MHz, methanol-d4) δ 7.90−7.84 (m, 2H), 7.58 (d, J = 3.8
Hz, 1H), 7.38−7.32 (m, 2H), 7.04 (d, J = 3.8 Hz, 1H), 4.02 (s, 2H),
3.03 (s, 3H). 13C NMR (126 MHz, methanol-d4) δ 156.79, 146.06,
142.74, 136.92, 134.52, 130.00, 126.62, 119.69, 41.34, 40.06. HRMS
(ESI) for C12H15N2O4S3 ([M + H]
+): calculated 347.0189; observed
347.0190; error = 0.29 ppm.
(5-(4-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)-
methanamine (3i). 5-((4-(Methylsulfonyl)phenyl)sulfonyl)-
thiophene-2-carbonitrile was synthesized according to general
procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile
(500 mg, 3.48 mmol), 4-(methylthio)benzenethiol (599 mg, 3.83
mmol), K2CO3 (960 mg, 7.00 mmol), and DMF (11.6 mL), 120 °C,
16 h and (ii) mCPBA (77%; 3.90 g, 17.4 mmol) and DCM (23 mL),
rt, 2 h. A white solid was obtained, which did not require further
purification (770 mg, 68%). 1H NMR (500 MHz, DMSO-d6) δ 8.35−
8.29 (m, 2H), 8.24−8.18 (m, 2H), 8.13−8.08 (m, 2H), 3.31 (s, 3H).
13C NMR (126 MHz, DMSO-d6) δ 147.29, 145.83, 144.19, 140.29,
134.79, 128.78, 128.56, 116.87, 112.57, 42.92.
Compound 3i was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 8.40 mL, 8.40 mmol), 5-((4-
(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile (921 mg,
2.81 mmol), and THF (18 mL), 50 °C, 3 h. Chromatography
(MeOH/DCM 0 → 20%) afforded a white solid (310 mg, 34%). 1H
NMR (500 MHz, chloroform-d) δ 8.19−8.15 (m, 2H), 8.11−8.06
(m, 2H), 7.63 (d, J = 3.9 Hz, 1H), 6.93 (dt, J = 3.8, 1.0 Hz, 1H), 4.09
(d, J = 0.8 Hz, 2H), 3.08 (s, 3H), 1.61 (s, 2H). 13C NMR (126 MHz,
chloroform-d) δ 160.12, 147.61, 144.80, 138.67, 134.95, 128.64,
128.46, 124.12, 44.41, 41.70. HRMS (ESI) for C12H14NO4S3 ([M +
H]+): calculated 332.0080; observed 332.0070; error = 3.0 ppm.
(5-(4-(Methylsulfonyl)butylsulfonyl)thiophen-2-yl)-
methanamine (3j). A mixture of 2-methyl-5-((4-(methylsulfonyl)-
butyl)sulfonyl)thiophene 16 (860 mg, 2.90 mmol), Bz2O2 (75%; 46.8
mg, 0.145 mmol), NBS (568 mg, 3.19 mmol), and DCE (14.5 mL)
was stirred at 70 °C for 16 h. The solvent was removed under reduced
pressure, and the crude was dissolved in DMF (14.5 mL). NaN3 (226
mg, 3.40 mmol) was added and the mixture was stirred at 70 °C for 5
h. After cooling to rt, EtOAc (30 mL) was added. The organic phase
was washed with 1:1 H2O/brine (3 × 30 mL), dried over MgSO4, and
filtered. The solvent was removed under reduced pressure, and the
crude was purified by chromatography (EtOAc/DCM 5 → 30%) to
afford 2-(azidomethyl)-5-((4-(methylsulfonyl)butyl)sulfonyl)-
thiophene as a colorless oil (414 mg, 42%). 1H NMR (500 MHz,
chloroform-d) δ 7.61 (d, J = 3.9 Hz, 1H), 7.09 (m, 1H), 4.59 (s, 2H),
3.33−3.22 (m, 2H), 3.13−3.01 (m, 2H), 2.92 (s, 3H), 2.13−1.92 (m,
4H). LCMS (ESI) m/z 360 [M + Na]+.
A mixture of (azidomethyl)-5-((4-(methylsulfonyl)butyl)sulfonyl)-
thiophene (410 mg, 1.22 mmol) and Pd/C (10%; 129 mg, 0.122
mmol) in THF (6.1 mL) was stirred at rt under H2 atmosphere
(balloon) for 16 h and subsequently filtered through celite. The
solvent was removed under reduced pressure, and the crude was
purified by chromatography (MeOH/DCM 0 → 20%) to afford
compound 3j as a white solid (27 mg, 6%). 1H NMR (500 MHz,
chloroform-d) δ 7.54 (d, J = 3.8 Hz, 1H), 6.95 (mm, 1H), 4.11 (s,
2H), 3.25−3.19 (m, 2H), 3.05−3.00 (m, 2H), 2.89 (s, 3H), 2.03−
1.91 (m, 4H), 1.71 (s, 2H). 13C NMR (126 MHz, chloroform-d) δ
158.73, 137.14, 134.65, 123.97, 56.81, 53.92, 41.63, 40.85, 22.16,
21.11. HRMS (ESI) for C10H18NO4S3 ([M + H]
+): calculated
312.0393; observed 312.0417; error = 7.7 ppm.
(5-(Phenylsulfinyl)thiophen-2-yl)methanamine (4a). 5-
(Phenylsulfinyl)thiophene-2-carbonitrile was synthesized according
to general procedures GP5, from mCPBA (77%; 143 mg, 0.636
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mmol) and 5-(phenylthio)thiophene-2-carbonitrile 29 (138 mg,
0.636 mmol) in DCM (3 mL), rt, 16 h. Chromatography (EtOAc/
cyclohexane 0 → 20%) afforded a colorless oil (127 mg, 86%). 1H
NMR (500 MHz, chloroform-d) δ 7.76−7.70 (m, 2H), 7.60−7.50
(m, 4H), 7.44 (d, J = 4.0 Hz, 1H). LCMS (ESI) m/z 233 [M + H]+.
Compound 4a was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 1.70 mL, 1.70 mmol), 5-(naphthalen-
2-ylsulfonyl)thiophene-2-carbonitrile (132 mg, 0.568 mmol), and
THF (2.8 mL), rt, 2 h. Chromatography (MeOH/DCM 0 → 20%)
afforded a yellow oil (53 mg, 40%). 1H NMR (500 MHz, chloroform-
d) δ 7.72−7.65 (m, 2H), 7.54−7.43 (m, 4H), 6.86 (m, 1H), 4.00 (s,
2H), 1.80 (s, 2H). 13C NMR (126 MHz, chloroform-d) δ 156.03,
145.85, 145.18, 132.03, 131.13, 129.26, 124.42, 123.46, 41.74. HRMS
(ESI) for C11H12NOS2 ([M + H]
+): calculated 238.0355; observed
238.0378; error = 9.7 ppm.
(5-(Phenylthio)thiophen-2-yl)methanamine Hydrochloride
(4b). The titled compound was synthesized according to general
procedure GP2, from 4 M HCl in dioxane (2.5 mL) and tert-butyl
((5-(phenylthio)thiophen-2-yl)methyl)carbamate (60.1 mg, 0.189
mmol), rt, 3 h. A white solid was obtained, which did not require
further purification (29 mg, 60%). 1H NMR (500 MHz, methanol-d4)
δ 7.36−7.14 (m, 7H), 4.32 (s, 2H). 13C NMR (126 MHz, methanol-
d4) δ 141.06, 138.75, 136.99, 135.89, 131.40, 130.24, 129.20, 127.91,
38.79. HRMS (ESI) for C11H9S2 ([M − NH2]+): calculated
205.0146; observed 205.1050; error = 2.0 ppm.
5-(Aminomethyl)-N-benzylthiophene-2-sulfonamide (4c).
The titled compound was synthesized according to general procedure
GP1, from (i) sulfonyl chloride 11a (100 mg, 0.325 mmol),
benzylamine (88.7 μL, 0.812 mmol), and DCM (1.63 mL), 16 h, rt
and (ii) 30% NaOH (0.5 mL) and MeOH (3 mL), rt, 16 h. A
colorless oil (59 mg, 64%) was obtained, which did not require further
purification. 1H NMR (500 MHz, chloroform-d) δ 7.44 (d, J = 3.7 Hz,
1H), 7.32−7.20 (m, 5H), 6.84 (d, J = 3.6 Hz, 1H), 5.24 (br, 1H),
4.19 (s, 2H), 4.02 (s, 2H), 1.87 (br, 2H). 13C NMR (126 MHz,
chloroform-d) δ 132.60, 128.77, 128.02, 127.98, 123.55, 47.50, 41.43.
HRMS (ESI) for C12H15N2O2S2 ([M + H]
+): calculated 283.0570;
observed 283.0573; error = 1.1 ppm.
5-(Aminomethyl)-N-benzylthiophene-2-carboxamide (4d).
A mixture of methyl 5-(azidomethyl)thiophene-2-carboxylate 44 (A
= S) (1.77 g, 8.98 mmol), 1 M NaOH (30 mL), and MeOH (30 mL)
was stirred at rt for 16 h. The pH was subsequently adjusted to <2
with 2 M HCl. The aqueous phase was extracted with DCM (3 × 30
mL). The combined organic phase was dried over MgSO4 and
filtered, and the solvent was removed under reduced pressure. The
crude was dissolved in DCM (21.8 mL), and oxalyl chloride (0.61
mL, 7.20 mmol) was added, followed by DMF (two drops). The
mixture was stirred at rt for 3 h, and the solvent was removed under
reduced pressure to afford acyl chloride 45 (A = S) as an orange oil
(1.25 g, 75%). Acyl chloride 45 was used in the subsequent
transformation without further purification
Benzylamine (120 μL, 1.09 mmol) was added to a solution of acyl
chloride 45 (100 mg, 0.496 mmol) and DCM (2.5 mL), and the
mixture was stirred at rt for 3 h. Two molar HCl (10 mL) was added,
and the aqueous phase was extracted with DCM (3 × 10 mL). The
combined organic phase was dried over MgSO4, filtered, and the
solvent was removed under reduced pressure. The crude was
dissolved in THF (2.5 mL), and 10% Pd/C (53 mg) was added.
The mixture was stirred under a H2 atmosphere (balloon) at rt for 24
h and was subsequently filtered through celite. The solvent was
removed under reduced pressure, and the crude was purified by
chromatography (1 N NH3 in MeOH/DCM 0 → 20%) to afford
compound 4d as a white solid (55 mg, 45%). 1H NMR (500 MHz,
methanol-d4) δ 7.36−7.19 (m, 5H), 7.04 (d, J = 3.4 Hz, 1H), 6.37 (d,
J = 3.3 Hz, 1H), 4.52 (s, 2H), 3.81 (s, 2H). 13C NMR (126 MHz,
methanol-d4) δ 160.84, 159.70, 147.96, 140.02, 129.53, 128.59,
128.25, 116.26, 109.12, 43.74, 39.37. HRMS (ESI) for C13H15N2OS
([M + H]+): calculated 247.0905; observed 247.0907; error = 0.81
ppm.
(5-(4-(Methylsulfonyl)phenyl)thiophen-2-yl)methanamine
Hydrochloride (4e). The titled compound was synthesized
according to general procedures GP2, from tert-butyl ((5-(4-
(methylsulfonyl)phenyl)thiophen-2-yl)methyl)carbamate 59 (267
mg, 0.797 mmol), 4 M HCl in dioxane (4 mL), and DCM (4 mL),
rt, 16 h. A light yellow solid was obtained that did not require further
purification (138 mg, 64%). 1H NMR (500 MHz, methanol-d4) δ
8.01−7.96 (m, 2H), 7.93−7.89 (m, 2H), 7.57 (d, J = 3.7 Hz, 1H),
7.29 (d, J = 3.8 Hz, 1H), 4.36 (s, 2H), 3.16 (s, 3H). 13C NMR (126
MHz, methanol-d4) δ 144.98, 140.90, 140.20, 137.74, 131.83, 129.37,
127.31, 126.97, 44.36, 38.86. HRMS (ESI) for C12H11O2S2 ([M −
NH2]
+): calculated 251.0200; observed 251.0196; error = 1.6 ppm.
(6-(Benzylsulfonyl)pyridin-3-yl)methanamine Dihydro-
chloride (5a). The titled compound was synthesized according to
general procedures GP5 and GP2, from (i) sulfide 47 (44 mg, 0.133
mmol), mCPBA (50%; 115 mg, 0.333 mmol), and DCM (0.6 mL) at
rt for 16 h and (ii) 2 M HCl in Et2O (2.0 mL), DCM (1.0 mL), rt, 20
h. Chromatography (1 N NH3 in MeOH/DCM 0 → 20%) afforded a
white solid (27 mg, 77%). 1H NMR (500 MHz, methanol-d4) δ 8.76
(m, 1H), 7.92 (m, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.30−7.16 (m, 5H),
4.68 (s, 2H), 3.92 (s, 2H). 13C NMR (126 MHz, methanol-d4) δ
155.78, 150.77, 144.38, 138.22, 132.22, 129.66, 129.53, 129.19,
129.14, 124.10, 59.32, 43.72. HRMS (ESI) for C13H15N2O2S ([M +
H]+): calculated 263.0849; observed 263.0848; error = 0.38 ppm.
(5-(Benzylsulfonyl)thiophen-2-yl)methanamine (5b). 5-
(Benzylsulfonyl)thiophene-2-carbonitrile was synthesized according
to general procedures GP4 and GP5, from (i) 5-bromothiophene-2-
carbonitrile 17a (150 μL, 1.35 mmol), benzylmercaptan (174 μL,
1.49 mmol), NaH (60% in mineral oil; 59.5 mg, 1.49 mmol), and
DMF (4.5 mL), 140 °C, 16 h and (ii) mCPBA (77%; 757 mg, 3.38
mmol) and DCM (4.5 mL), rt, 4 h. Chromatography (EtOAc/
cyclohexane 0 → 20%) afforded a white solid (318 mg, 89%). 1H
NMR (500 MHz, DMSO-d6) δ 8.07 (d, J = 4.0 Hz, 1H), 7.72 (d, J =
4.0 Hz, 1H), 7.40−7.32 (m, 3H), 7.25−7.18 (m, 2H), 4.93 (s, 2H).
LCMS (ESI) m/z 286 [M + Na]+.
Compound 5b was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 1.10 mL, 1.10 mmol), 5-
(benzylsulfonyl)thiophene-2-carbonitrile (151 mg, 0.570 mmol),
and THF (2.8 mL) at rt for 1 h. Chromatography (MeOH/DCM
0 → 20%) afforded a white crystalline solid (23 mg, 15%). 1H NMR
(500 MHz, chloroform-d) δ 7.38−7.26 (m, 3H), 7.21−7.15 (m, 3H),
6.84 (dt, J = 3.8, 1.0 Hz, 1H), 4.39 (s, 2H), 4.07 (d, J = 0.9 Hz, 2H),
1.59 (s, 2H). 13C NMR (126 MHz, chloroform-d) δ 158.50, 136.25,
135.25, 130.88, 129.00, 128.74, 128.52, 123.68, 64.15, 41.68. HRMS
(ESI) for C12H14NO2S2 ([M + H]
+): calculated 268.0461; observed
268.0462; error = 0.37 ppm.
( 2 - ( N a p h t h a l e n - 2 - y l s u l f o n y l ) t h i a z o l - 5 - y l ) -
methanamine hydrochloride (5c). tert-Butyl ((2-(naphthalen-2-
ylthio)thiazol-5-yl)methyl)carbamate was synthesized according to
general procedures GP4, GP3, and GP6, from (i) 2-chlorothiazole-5-
carbonitrile 17b (580 mg, 4 mmol), naphthalene-2-thiol (640 mg, 4
mmol), K2CO3 (800 mg, 5.8 mmol), and DMF (10 mL) at 60 °C for
24 h. Chromatography (DCM/cyclohexane 0→ 100%) 400 mg, 37%;
(ii) 2-(naphthalen-2-ylthio)thiazole-5-carbonitrile (400 mg, 1.5
mmol), BH3 (1.0 M in THF; 5 mL, 5 mmol), THF (20 mL) at rt
for 18 h. Chromatography (EtOAc/DCM 0 → 100%) 120 mg, 26%;
(iii) (2-(naphthalen-2-ylthio)thiazol-5-yl)methanamine (120 mg, 0.4
mmol), Boc2O (109 mg, 0.5 mmol), Et3N (70 μL, 0.5 mmol), THF
(5 mL), rt, 18 h. Chromatography (EtOAc/DCM 0→ 50%) to afford
tert-butyl ((2-(naphthalen-2-ylthio)thiazol-5-yl)methyl)carbamate
(110 mg, 74%). 1H NMR (500 MHz, DMSO-d6) δ 8.79 (d, J = 1.9
Hz, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 8.09 (d, J
= 8.1 Hz, 1H), 7.95 (dd, J = 8.6, 2.0 Hz, 1H), 7.91 (s, 1H), 7.82−7.75
(m, 1H), 7.72 (ddd, J = 8.0, 6.9, 1.3 Hz, 1H), 7.65 (t, J = 6.1 Hz, 1H),
4.36 (d, J = 6.0 Hz, 2H), 1.38 (s, 9H). LCMS (ESI) m/z 373 [M +
H]+.
Compound 5c was synthesized according to general procedures
GP5 and GP2, from (i) tert-butyl ((2-(naphthalen-2-ylthio)thiazol-5-
yl)methyl)carbamate (110 mg, 0.296 mmol), mCPBA (77%; 340 mg,
1.52 mmol), and DCM (5.0 mL) at rt for 3 h and (ii) 4 M HCl in
dioxane (2.0 mL) and dioxane (5 mL), at rt, for 16 h. The white
precipitate was filtered, washed with excess dioxane, and dried under
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vacuum to afford the desired compound as a white solid (33 mg,
37%). 1H NMR (500 MHz, DMSO-d6) δ 8.82 (d, J = 2.0 Hz, 1H),
8.49 (s, 3H), 8.31 (d, J = 8.2 Hz, 1H), 8.23 (d, J = 8.7 Hz, 1H), 8.15
(s, 1H), 8.10 (d, J = 8.1 Hz, 1H), 7.97 (dd, J = 8.6, 2.1 Hz, 1H),
7.84−7.77 (m, 1H), 7.77−7.71 (m, 1H), 4.39 (s, 2H). HRMS (ESI)
for C14H13N2O2S2 [M + H]
+: calculated 305.0413; observed
305.0471; error = 19 ppm.
(5-(Naphthalen-2-ylsulfonyl)thiazol-2-yl)methanamine Hy-
drochloride (5d). The titled compound was synthesized according
to general procedures GP5 and GP2, from (i) tert-butyl ((5-
(naphthalen-2-ylthio)thiazol-2-yl)methyl)carbamate 49 (200 mg,
0.537 mmol), mCPBA (77%; 300 mg, 1.34 mmol), and DCM (4
mL) at rt for 18 h; chromatography (EtOAc/cyclohexane 0 → 60%)
and (ii) 4 M HCl in dioxane (1.6 mL) at rt for 4 h. The mixture was
diluted with Et2O and the precipitate collected using filtration, washed
with excess Et2O, and dried under vacuum to afford the compound as
a white solid (106 mg, 52% over two steps). 1H NMR (DMSO-d6,
500 MHz) δ 8.79 (d, 1H, J = 1.8 Hz), 8.72 (br s, 3H), 8.65 (s, 1H),
8.27 (d, 1H, J = 8.4 Hz), 8.21 (d, 1H, J = 8.8 Hz), 8.09 (d, 1H, J = 8.2
Hz), 8.00 (dd, 1H, J = 8.7, 2.0 Hz), 7.78 (ddd, 1H, J = 8.2, 6.9, 1.3
Hz), 7.73 (ddd, 1H, J = 8.1, 6.9, 1.3 Hz), 4.46 (s, 2H); 13C NMR
(DMSO-d6, 125 MHz) δ 170.3, 147.4, 140.2, 137.6, 134.9, 131.8,
130.4, 130.0, 129.7, 128.8, 128.2, 128.0, 121.8, 39.7; HRMS (ESI) for
C14H13N2S2O2 [M + H]
+: calculated 305.0402; observed 305.0413;
error = 3.6 ppm.
5-(Aminomethyl)-N-benzylfuran-2-carboxamide (5e). Ben-
zylamine (130 μL, 1.19 mmol) was added to a solution of acyl
chloride 45 (A = O; 100 mg, 0.539 mmol) and DCM (2.7 mL), and
the mixture was stirred at rt for 1 h. Two molar HCl (10 mL) was
added, and the aqueous phase was extracted with DCM (3 × 10 mL).
The combined organic phase was dried over MgSO4 and filtered, and
the solvent was removed under reduced pressure. The crude was
dissolved in THF (2.7 mL), and 10% Pd/C (57.3 mg) was added.
The mixture was stirred under a H2 atmosphere (balloon) at rt for 20
h and was subsequently filtered through celite. The solvent was
removed under reduced pressure, and the crude was purified by
chromatography (1 N NH3 in MeOH/DCM 0 → 20%) to afford
compound 5e as a light brown oil (48 mg, 39%). 1H NMR (500
MHz, methanol-d4) δ 7.56 (d, J = 3.8 Hz, 1H), 7.38−7.18 (m, 5H),
6.98 (d, J = 3.8 Hz, 1H), 4.51 (s, 2H), 3.96 (s, 2H). 13C NMR (126
MHz, methanol-d4) δ 164.43, 152.94, 140.21, 138.59, 129.85, 129.56,
128.56, 128.22, 126.28, 44.41, 41.61. HRMS (ESI) for
C13H14N2O2Na ([M + Na]
+): calculated 253.0953; observed
253.0960; error = 2.8 ppm.
(5-( Indolin-1-ylsulfonyl)-4-methylthiophen-2-yl ) -
methanamine (5f). The titled compound was synthesized according
to general procedure GP1, from (i) sulfonyl chloride 11b (crude),
Et3N (44.4 μL, 0.319 mmol), indoline (33 μL, 0.294 mmol), and
DCM (1.2 mL), rt, 3 h; (ii) 7 N NH3 in MeOH (5 mL), rt for 20 h.
Chromatography (1 N NH3 in MeOH/DCM 0 → 10%) afforded a
compound as a light brown foam (54 mg, 73%). 1H NMR (500 MHz,
chloroform-d) δ 7.59 (d, J = 8.1 Hz, 1H), 7.21−7.10 (m, 2H), 7.00
(td, J = 7.4, 0.9 Hz, 1H), 6.68 (s, 1H), 4.03 (t, J = 8.4 Hz, 2H), 3.96
(s, 2H), 2.97 (t, J = 8.3 Hz, 2H), 2.33 (s, 3H), 1.68−1.35 (br, 2H).
13C NMR (126 MHz, chloroform-d) δ 153.13, 143.82, 141.96,
132.09, 129.42, 127.97, 127.69, 125.15, 124.08, 115.79, 50.22, 41.39,
28.16, 15.56. HRMS (ESI) for C14H17N2O2S2 ([M + H]
+): calculated
309.0726; observed 309.0726; error = 0 ppm.
N-Methyl-1-(5-(phenylsulfonyl)thiophen-2-yl)methanamine
Hydrochloride (6a). The titled compound was synthesized
according to general procedure GP2, from tert-butyl methyl((5-
(phenylsulfonyl)thiophen-2-yl)methyl)carbamate (57 mg, 0.155
mmol) and 4 M HCl in dioxane (2.5 mL) at rt for 16 h.
Chromatography (EtOH/cyclohexane 50 → 100%) afforded a white
solid (43 mg, quant.). 1H NMR (500 MHz, methanol-d4) δ 8.01−7.93
(m, 2H), 7.67−7.55 (m, 4H), 7.05 (d, J = 3.8 Hz, 1H), 3.93 (s, 2H),
2.38 (s, 3H). 13C NMR (126 MHz, methanol-d4) δ 154.35, 143.60,
142.54, 134.90, 134.63, 130.61, 128.22, 127.79, 50.42, 35.41. HRMS
(ESI) for C12H14NO2S2 ([M + H]
+): calculated 268.0461; observed
268.0457; error = 1.5 ppm.
1-(5-(Phenylsulfonyl)thiophen-2-yl)ethanamine (6b). A mix-
ture of sulfone 41 (177 mg, 0.665 mmol), hydroxylamine hydro-
chloride (76 mg, 1.10 mmol), and DIPEA (174 μL, 1.00 mmol) in
EtOH (10 mL) was stirred at reflux for 18 h. After cooling to rt, the
solvent was removed under reduced pressure. The crude was purified
by chromatography (EtOAc/DCM 0 → 100%) to afford 1-(5-
(phenylsulfonyl)thiophen-2-yl)ethanone oxime (80 mg, 43%). 1H
NMR (500 MHz, DMSO-d6) δ 11.72 (s, 1H), 8.01−7.95 (m, 2H),
7.79 (d, J = 4.0 Hz, 1H), 7.75−7.70 (m, 1H), 7.68−7.62 (m, 2H),
7.41 (d, J = 4.0 Hz, 1H), 2.14 (s, 3H).
A mixture of 1-(5-(phenylsulfonyl)thiophen-2-yl)ethanone oxime
(80 mg, 0.142 mmol), Zn powder (∼10 mg), and TFA (4 mL) was
stirred at rt for 1 h. The mixture was diluted with DCM and filtered
through celite, and the solvent was removed under reduced pressure.
EtOAc was added, and the solution was washed with sat. NaHCO3,
dried over MgSO4, and filtered, and the solvent was removed under
reduced pressure to afford compound 6b (17 mg, 43%). 1H NMR
(500 MHz, DMSO-d6) δ 7.96−7.92 (m, 2H), 7.70−7.67 (m, 2H),
7.65−7.61 (m, 2H), 7.01 (dd, J = 3.9, 1.0 Hz, 1H), 4.21 (qd, J = 6.5,
1.0 Hz, 1H), 2.40 (s, 2H), 1.30 (d, J = 6.6 Hz, 3H). LCMS (ESI) m/z
251 [M − NH2]+.
5-(Phenylsulfonyl)thiophene-2-carbonitrile (6c). The titled
compound can be obtained in two steps from the method illustrated
in Scheme 3 in the manuscript. An alternative one-step method is
shown here: A mixture of 5-bromothiophene-2-carbonitrile 17a (100
mg, 0.532 mmol), sodium benzenesulfinate (138 mg, 0.691 mmol),
and DMF (1.0 mL) was stirred at 135 °C for 16 h. After cooling to rt,
EtOAc (10 mL) was added. The organic phase was washed with H2O
(2 × 10 mL) and brine (10 mL), dried over MgSO4, and filtered. The
solvent was removed under reduced pressure, and the crude was
purified by chromatography (EtOAc/cyclohexane 0→ 20%) to afford
nitrile 6c as a white crystalline solid (67 mg, 51%). 1H NMR (500
MHz, chloroform-d) δ 8.03−7.98 (m, 2H), 7.70−7.53 (m, 5H). 13C
NMR (126 MHz, chloroform-d) δ 150.24, 140.54, 137.42, 134.47,
132.39, 129.89, 127.86, 117.10, 112.37. HRMS (ESI) for
C11H7NO2S2 ([M + H]
+): calculated 249.9996; observed 250.0001;
error = 2.0 ppm.
5-(Phenylsulfonyl)thiophene-2-carboximidamide Hydro-
chloride (6d). LiHMDS (225 mg, 1.35 mmol) was added to a
mixture of nitrile 6c (224 mg, 0.900 mmol) in Et2O (10 mL), and the
mixture was stirred at rt for 1 h. Two molar HCl (5 mL) was added,
and the mixture was stirred for a further 1 h. The aqueous layer was
washed with Et2O, basified with NaOH pellets, and extracted with
Et2O. The combined organic phase was dried over MgSO4 and
filtered, and the solvent was removed under reduced pressure to
afford compound 6d as a yellow solid (40 mg, 16%). 1H NMR (500
MHz, methanol-d4) δ 8.07 (d, J = 6.9 Hz, 2H), 7.89 (br s, 2H), 7.54−
7.80 (m, 3H). 13C NMR (126 MHz, methanol-d4) δ 160.8, 151.3,
142.2, 137.2, 135.8, 135.1, 134.9, 131.2, 129.0. HRMS (ESI) for
C11H10N2O2S2 [M + H]
+: calculated 267.0256; observed 267.0301;
error = 17 ppm.
5-(Phenylsulfonyl)thiophene-2-carboxamide (6e). A mixture
of nitrile 6c (100 mg, 0.401 mmol), InCl3 (4.4 mg, 5%), and
acetaldoxime (76 mg, 1.21 mmol) in toluene (0.4 mL) was stirred at
reflux for 5 h. The solvent was removed under reduced pressure, and
the crude was purified by chromatography (EtOAc/cyclohexane 20→
80%) to afford compound 6e as a yellow gel (52 mg, 50%). 1H NMR
(500 MHz, CD3OD) δ 7.94−8.10 (m, 2H), 7.66−7.75 (m, 3H),
7.59−7.66 (m, 2H). 13C NMR (126 MHz, CD3OD) δ 164.8, 148.5,
148.3, 142.9, 135.2, 134.8, 130.9, 130.2, 128.7. HRMS (ESI) for
C11H9NO3S2 [M + H]
+: calculated 268.0097; observed 268.0187;
error = 34 ppm.
5-(Naphthalen-2-ylsulfonyl)thiophene-2-carbaldehyde
Oxime (6f). DIBAL-H (1.0 M in toluene; 1.0 mL, 1.0 mmol) was
added to a solution of 5-(naphthalen-2-ylsulfonyl)thiophene-2-
carbonitrile 43 (104 mg, 0.347 mmol) in DCM (3 mL) at rt. The
mixture was stirred at 45 °C for 45 min and cooled in an ice bath.
Two molar H2SO4 was added followed by stirring for a further 1 h at
rt. The aqueous phase was extracted with DCM. The organic phase
was washed with H2O and sat. NaHCO3, dried over Na2SO4, and
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filtered, and the solvent was removed under reduced pressure. The
crude was purified by column chromatography (EtOAc/cyclohexane
0 → 30%) to afford 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbalde-
hyde as a yellow solid (96 mg, 92%). 1H NMR (500 MHz,
chloroform-d) δ 9.92 (s, 1H), 8.62 (s, 1H), 8.07−7.96 (m, 2H),
7.96−7.87 (m, 2H), 7.78 (d, J = 3.8 Hz, 1H), 7.72−7.61 (m, 3H).
HRMS (ESI) for C15H10O3S2 [M + H]
+: calculated 303.0144;
observed 303.0159; error = 5.0 ppm.
A mixture of 5-(naphthalen-2-ylsulfonyl)thiophene-2-carbaldehyde
(96 mg, 0.318 mmol), hydroxylamine hydrochloride (28 mg, 0.406
mmol), and K2CO3 (132 mg, 0.957 mmol) in EtOH (6.0 mL) was
stirred 70 °C for 2 h. After cooling to rt, the mixture was filtered and
the solvent was removed under reduced pressure. The crude was
purified by chromatography (EtOAc/cyclohexane) to afford oxime 6f
as a white solid (38 mg, 38%). 1H NMR (500 MHz, chloroform-d) δ
8.61 (s, 1H), 7.95−8.08 (m, 2H), 7.87−7.95 (m, 2H), 7.58−7.74 (m,
4H), 7.41 (d, J = 4.1 Hz, 1H), 5.8 (br s, OH). 13C NMR (126 MHz,
chloroform-d) δ 161.8, 147.8, 145.1, 137.9, 135.3, 132.8, 132.2, 129.9,
129.5, 129.3, 128.5, 128.0, 127.9, 122.3. HRMS (ESI) for
C15H11NO3S2 [M − OH]+: calculated 300.0153; observed
300.0192; error = 13 ppm.
(3-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine
(7a). The titled compound was synthesized according to general
procedure GP3, from BH3 (1.0 M in THF; 6.0 mL, 6.0 mmol), 3-
(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile 52 (602 mg, 2.01
mmol), and THF (6.0 mL), for 2 h, at rt. Chromatography (EtOH/
cyclohexane 0 → 90%) afforded a white crystalline solid (289 mg,
48%). 1H NMR (500 MHz, chloroform-d) δ 8.55 (d, J = 1.5 Hz, 1H),
8.00 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 8.7 Hz, 1H), 7.90 (d, J = 8.0 Hz,
1H), 7.84 (dd, J = 8.7, 1.9 Hz, 1H), 7.69−7.60 (m, 2H), 7.42 (d, J =
5.4 Hz, 1H), 7.20 (d, J = 5.4 Hz, 1H), 4.31 (s, 2H), 1.92 (s, 2H). 13C
NMR (126 MHz, chloroform-d) δ 154.77, 138.97, 135.19, 135.00,
132.29, 129.85, 129.57, 129.32, 128.68, 128.45, 128.09, 127.85,
124.02, 122.36, 40.04. HRMS (ESI) for C15H14NO2S2 ([M + H]
+):
calculated 304.0460; observed 304.0462; error = 0.66 ppm.
(4-(Naphthalen-2-ylsulfonyl)thiophen-3-yl)methanamine
(7b). The titled compound was synthesized according to general
procedure GP3, from BH3 (1.0 M in THF; 8.2 mL, 8.2 mmol), 4-
(naphthalen-2-ylsulfonyl)thiophene-3-carbonitrile 54 (0.821 g, 2.75
mmol), and THF (8.2 mL); 2 h, rt. Chromatography (EtOH/
cyclohexane 0 → 100%) afforded a white crystalline solid (386 mg,
47%). 1H NMR (500 MHz, chloroform-d) δ 8.55 (br, 1H), 8.27 (d, J
= 3.4 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.87
(d, J = 8.0 Hz, 1H), 7.79 (dd, J = 8.7, 1.8 Hz, 1H), 7.71−7.53 (m,
2H), 7.26 (d, J = 14.5 Hz, 1H), 3.85 (s, 2H), 1.82−1.54 (m, 2H). 13C
NMR (126 MHz, chloroform-d) δ 142.19, 138.80, 137.83, 135.08,
134.87, 132.08, 129.73, 129.46, 129.34, 128.86, 127.98, 127.79,
124.96, 122.48, 77.42, 77.17, 76.92, 40.35. HRMS (ESI) for
C15H14NO2S2 ([M + H]
+): calculated 304.0460; observed
304.0460; error = 0 ppm.
(4-(Naphthalen-2-ylsulfonyl)thiophen-2-yl)methanamine
(7c). The titled compound was synthesized according to general
procedure GP3, from BH3 (1.0 M in THF; 5.0 mL, 5.0 mmol), 4-
(naphthalen-2-ylsulfonyl)thiophene-2-carbonitrile 56 (501 mg, 1.68
mmol), and THF (5.0 mL), 2 h, rt. Chromatography (EtOH/
cyclohexane 5 → 100%) afforded a light orange solid (256 mg, 51%).
1H NMR (500 MHz, chloroform-d) δ 8.57 (s, 1H), 8.02 (s, 1H),
8.00−7.91 (m, 2H), 7.90−7.84 (m, 2H), 7.67−7.54 (m, 2H), 7.16 (s,
1H), 3.97 (s, 2H), 1.71 (s, 2H). 13C NMR (126 MHz, chloroform-d)
δ 151.36, 141.20, 138.42, 135.07, 132.24, 130.33, 129.71, 129.44,
129.20, 128.89, 127.99, 127.70, 122.56, 121.52, 41.27. HRMS (ESI)
for C15H14NO2S2 ([M + H]
+): calculated 304.0460; observed
304.0444; error = 5.2 ppm.
(5-(3-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)-
methanamine (8a). 5-((3-(Methylsulfonyl)phenyl)sulfonyl)-
thiophene-2-carbonitrile was synthesized according to general
procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile
17a (120 μL, 1.14 mmol), 3-(methylthio)benzenethiol (178 mg, 1.14
mmol), K2CO3 (157 mg, 1.14 mmol), and DMF (5.7 mL), 120 °C, 16
h and (ii) mCPBA (77%; 1.15 g, 5.13 mmol) and DCM (5.7 mL), rt,
16 h. Chromatography (EtOAc/DCM 5 → 30%) afforded a white
solid (207 mg, 56%). 1H NMR (500 MHz, chloroform-d) δ 8.57 (t, J
= 1.7 Hz, 1H), 8.28 (ddd, J = 7.9, 1.8, 1.1 Hz, 1H), 8.23 (ddd, J = 7.9,
1.6, 1.1 Hz, 1H), 7.83 (t, J = 7.9 Hz, 1H), 7.72 (d, J = 4.1 Hz, 1H),
7.60 (d, J = 4.1 Hz, 1H), 3.13 (s, 3H).
Compound 8a was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 0.88 mL, 0.88 mmol), 5-((3-
(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile (96 mg,
0.293 mmol), and THF (1.5 mL); rt, 1 h. Chromatography
(MeOH/DCM 0 → 20%) afforded a white solid (60 mg, 63%). 1H
NMR (500 MHz, chloroform-d) δ 8.50 (t, J = 1.6 Hz, 1H), 8.24 (ddd,
J = 7.9, 1.7, 1.1 Hz, 1H), 8.13 (ddd, J = 7.8, 1.7, 1.1 Hz, 1H), 7.74 (t, J
= 7.9 Hz, 1H), 7.62 (d, J = 3.9 Hz, 1H), 6.91 (dt, J = 3.9, 1.0 Hz, 1H),
4.07 (d, J = 0.9 Hz, 2H), 3.09 (s, 3H), 1.65 (s, 2H). 13C NMR (126
MHz, chloroform-d) δ 160.00, 144.45, 142.31, 138.59, 134.88,
132.21, 131.73, 130.82, 126.38, 124.12, 44.45, 41.64. HRMS (ESI) for
C12H11O4S3 ([M − NH2]+): calculated 314.9814; observed 314.9820;
error = 1.9 ppm.
(5-(2-(Methylsulfonyl)phenylsulfonyl)thiophen-2-yl)-
methanamine (8b). 5-((2-(Methylsulfonyl)phenyl)sulfonyl)-
thiophene-2-carbonitrile was synthesized according to general
procedures GP4 and GP5, from (i) 5-chlorothiophene-2-carbonitrile
17a (87.8 μL, 0.832 mmol), 2-(methylthio)benzenethiol (130 mg,
0.832 mmol), K2CO3 (172 mg, 1.25 mmol) and DMF (2.8 mL), 120
°C, 16 h and (ii) mCPBA (77%; 839 mg, 3.74 mmol) and DCM (2.8
mL), rt, 6 h. Chromatography (EtOAc/DCM 5 → 30%) afforded a
white solid (46 mg, 17%). 1H NMR (500 MHz, chloroform-d) δ 8.47
(m, 1H), 8.37 (m, 1H), 7.96−7.87 (m, 3H), 7.54 (d, J = 4.1 Hz, 1H),
3.49 (s, 3H).
Compound 8b was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 0.41 mL, 0.41 mmol), 5-((2-
(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile (45 mg,
0.137 mmol) and THF (0.8 mL), rt, 1 h. Chromatography
(MeOH/DCM 0 → 20%) afforded compound 8b as a white solid
(17 mg, 39%). 1H NMR (500 MHz, chloroform-d) δ 8.43 (dd, J =
7.5, 1.7 Hz, 1H), 8.33 (dd, J = 7.6, 1.6 Hz, 1H), 7.88 (d, J = 3.9 Hz,
1H), 7.85−7.76 (m, 2H), 6.88 (dt, J = 3.9, 0.9 Hz, 1H), 4.06 (d, J =
0.8 Hz, 2H), 3.51 (s, 3H), 1.59 (s, 2H). 13C NMR (126 MHz,
chloroform-d) δ 159.33, 142.15, 139.62, 138.92, 136.80, 134.50,
134.07, 132.79, 132.44, 123.74, 45.73, 41.73. HRMS (ESI) for
C12H14NO4S3 ([M + H]
+): calculated 332.0080; observed 332.0108;
error = 8.4 ppm.
(5-((4-(Pyrrolidin-1-ylsulfonyl)phenyl)sulfonyl)thiophen-2-
yl)methanamine (8c). A mixture of 2,2,2-trifluoro-N-((5-((4-
(pyrrolidin-1-ylsulfonyl)phenyl)thio)thiophen-2-yl)methyl)acetamide
24c (91 mg, 0.202 mmol), mCPBA (77%; 100 mg, 0.444 mmol), and
DCM (1.4 mL) was stirred at rt for 4 h. EtOAc (30 mL) was added.
The organic phase was washed with sat. NaHCO3 (3 × 30 mL), dried
over MgSO4, and filtered. The solvent was removed under reduced
pressure. The crude was dissolved in 7 N NH3 in MeOH (3.0 mL),
and the mixture was stirred at rt for 16 h. The solvent was removed
under reduced pressure, and the crude was purified by chromatog-
raphy (EtOH/cyclohexane 5 → 40%, then 100%) to afford
compound 8c as a white solid (38 mg, 49%). 1H NMR (500 MHz,
methanol-d4) δ 8.20−8.15 (m, 2H), 8.04−8.00 (m, 2H), 7.70 (d, J =
3.9 Hz, 1H), 7.07 (m, 1H), 4.01 (s, 2H), 3.27−3.22 (m, 4H), 1.79−
1.73 (m, 4H). 13C NMR (126 MHz, methanol-d4) δ 159.72, 147.61,
143.08, 140.37, 136.09, 129.69, 129.18, 126.59, 49.15, 41.66, 26.28.
HRMS (ESI) for C15H19N2O4S3 ([M + H]
+): calculated 387.0502;
observed 387.0489; error = 3.4 ppm.
(5-((3-(Pyrrolidin-1-ylsulfonyl)phenyl)sulfonyl)thiophen-2-
yl)methanamine (8d). A mixture of 2,2,2-trifluoro-N-((5-((3-
(pyrrolidin-1-ylsulfonyl)phenyl)thio)thiophen-2-yl)methyl)acetamide
24d (107 mg, 0.238 mmol), mCPBA (77%; 117 mg, 0.523 mmol),
and DCM (1.6 mL) was stirred at rt for 4 h. EtOAc (30 mL) was
added. The organic phase was washed with sat. NaHCO3 (3 × 30
mL), dried over MgSO4, and filtered. The solvent was removed under
reduced pressure. The crude was dissolved in 7 N NH3 in MeOH (3.0
mL), and the mixture was stirred at rt for 16 h. The solvent was
removed under reduced pressure, and the crude was purified by
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chromatography (EtOH/cyclohexane 5 → 40%, then 100%) to afford
compound 8d as a white solid (49 mg, 51%). 1H NMR (500 MHz,
chloroform-d) δ 8.37 (br, 1H), 8.16 (m, J = 7.0 Hz, 1H), 8.00 (m, J =
7.2 Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.60 (m, 1H), 6.90 (br, 1H),
4.07 (br, 2H), 3.25 (br, 4H), 1.78 (br, 4H), 1.64 (br, 2H). 13C NMR
(126 MHz, chloroform-d) δ 159.69, 144.01, 139.17, 138.94, 134.64,
131.61, 131.00, 130.42, 126.07, 124.06, 48.17, 41.64, 25.40. HRMS
(ESI) for C15H19N2O4S3 ([M + H]
+): calculated 387.0502; observed
387.0493; error = 2.3 ppm.
(S)-(1-((3-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)-
sulfonyl)pyrrolidin-2-yl)methanol (8e). The titled compound was
synthesized according to general procedures GP5 and GP3, from (i)
(S)-5-((3-((2-(hydroxymethyl)pyrrolidin-1-yl)sulfonyl)phenyl)thio)-
thiophene-2-carbonitrile 23e (180 mg, 0.474 mmol), mCPBA (77%;
234 mg, 1.04 mmol) and DCM (3.2 mL), rt, 3 h and (ii) BH3 (1.0 M
in THF; 1.42 mL, 1.42 mmol) and THF (1.42 mL), rt, 1 h.
Chromatography (EtOH/cyclohexane 20 → 100%) afforded a white
foam (141 mg, 72%). 1H NMR (500 MHz, chloroform-d) δ 8.37 (t, J
= 1.8 Hz, 1H), 8.18 (dt, J = 7.9, 1.5 Hz, 1H), 8.02 (dt, J = 7.8, 1.4 Hz,
1H), 7.70 (t, J = 7.9 Hz, 1H), 7.60 (d, J = 3.8 Hz, 1H), 6.91 (m, 1H),
4.07 (d, J = 1.0 Hz, 2H), 3.69−3.58 (m, 3H), 3.45 (ddd, J = 10.4, 6.9,
5.2 Hz, 1H), 3.18 (dt, J = 10.4, 7.1 Hz, 1H), 2.13 (br, 3H), 1.88−1.75
(m, 2H), 1.70−1.58 (m, 1H), 1.55−1.43 (m, 1H). 13C NMR (126
MHz, chloroform-d) δ 159.51, 144.04, 139.01, 138.72, 134.73,
131.69, 131.20, 130.61, 126.10, 124.24, 65.27, 62.06, 50.01, 41.54,
28.72, 24.26. HRMS (ESI) for C16H20N2O5S3Na ([M + Na]
+):
calculated 439.0427; observed 439.0413; error = 3.2 ppm.
(5-((4-(Phenylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)-
methanamine (8f). The titled compound was synthesized according
to general procedure GP3, from 5-((4-(phenylsulfonyl)phenyl)-
sulfonyl)thiophene-2-carbonitrile 30 (40 mg, 0.103 mmol), BH3
(1.0 M in THF; 0.5 mL, 0.5 mmol), and THF (4.0 mL), rt, 3 h.
Chromatography (EtOH/cyclohexane 0 → 100%) afforded a glassy
solid (8 mg, 20%). 1H NMR (500 MHz, DMSO-d6) δ 8.21−8.13 (m,
4H), 7.99 (dt, J = 7.1, 1.3 Hz, 2H), 7.75 (d, J = 3.9 Hz, 1H), 7.73−
7.70 (m, 1H), 7.64 (t, J = 7.8 Hz, 2H), 7.02 (dt, J = 3.5, 1.2 Hz, 1H),
3.89 (d, J = 1.3 Hz, 2H), 2.45−2.13 (br, 2H). HRMS calcd for
C17H15NO4S3 [M + H]
+ 394.0236; found 394.0233; error = 0.76
ppm.
2-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)-
sulfonyl)ethanol Hydrochloride (8g). The titled compound was
synthesized according to general procedures GP2, from tert-butyl ((5-
((4-((2-hydroxyethyl)sulfonyl)phenyl)sulfonyl)thiophen-2-yl)-
methyl)carbamate 27 (n = 1) (52 mg, 0.113 mmol) and 4 M HCl in
dioxane (3.0 mL); rt, 3 h. A white solid was obtained, which did not
require further purification (39 mg, 87%). 1H NMR (500 MHz, D2O)
δ 8.37−8.29 (m, 2H), 8.27−8.19 (m, 2H), 7.91 (m, 1H), 7.38 (m,
1H), 4.48 (s, 2H), 4.03−3.95 (m, 2H), 3.72−3.65 (m, 2H). 13C NMR
(126 MHz, D2O) δ 146.18, 144.20, 140.94, 136.69, 131.43, 130.19,
129.18, 58.15, 55.77, 38.19. HRMS (ESI) for C13H13O5S3 ([M −
NH2]
+): calculated 344.9920; observed 344.9917; error = 0.87 ppm.
3-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)-
sulfonyl)propan-1-ol Hydrochloride (8h). The titled compound
was synthesized according to general procedure GP2, from 4 M HCl
in dioxane (1.5 mL) and tert-butyl ((5-((4-((3-hydroxypropyl)-
sulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 27 (n = 2)
23.5 mg, 0.0494 mmol; rt, 3 h. A white solid was obtained and did not
require further purification (23 mg, quant.). 1H NMR (500 MHz,
methanol-d4) δ 8.26 (d, J = 8.5 Hz, 2H), 8.15 (d, J = 8.5 Hz, 2H),
7.83 (d, J = 3.9 Hz, 1H), 7.34 (d, J = 3.9 Hz, 1H), 4.39 (s, 2H), 3.58
(t, J = 6.1 Hz, 2H), 3.37−3.32 (m, 2H), 1.89−1.80 (m, 2H). 13C
NMR (126 MHz, methanol-d4) δ 148.02, 146.19, 145.44, 144.33,
136.14, 131.84, 130.66, 129.60, 60.56, 53.60, 38.46, 26.85. HRMS
(ESI) for C14H18NO5S3 ([M + H]
+): calculated 376.0342; observed
376.0334; error = 2.1 ppm.
(5-((4-((2-(Pyrrolidin-1-yl)ethyl)sulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methanamine Dihydrochloride (8i). Pyrrolidine
(12.6 μL, 0.151 mmol) was added to a solution of tert-butyl ((5-((4-
(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 28
(61 mg, 0.138 mmol) in DCM (0.8 mL), and the mixture was
stirred at rt for 16 h. The solvent was removed under reduced
pressure. Four molar HCl in dioxane (4 mL) was added to the crude
and the mixture was stirred at rt for 16 h. The precipitated solid was
collected on a pad of celite and washed with EtOAc. MeOH was
added to dissolve the solid, and the suspension was filtered. The
solvent was removed under reduced pressure to afford compound 8i
as a white solid (58 mg, 85%), which did not require further
purification. 1H NMR (500 MHz, D2O) δ 8.37 (d, J = 7.9 Hz, 2H),
8.27 (d, J = 7.9 Hz, 2H), 7.92 (m, 1H), 7.41 (m, 1H), 4.51 (s, 2H),
3.99 (t, J = 7.2 Hz, 2H), 3.92−2.98 (m, 6H), 2.13 (br, 4H). 13C NMR
(126 MHz, D2O) δ 146.87, 145.89, 142.50, 140.91, 136.88, 131.77,
130.49, 129.53, 55.66, 51.65, 48.16, 38.08, 23.47. HRMS (ESI) for
C17H23N2O4S3 ([M + H]
+): calculated 415.0815; observed 415.0828;
error = 3.1 ppm.
N-(2-((4-((5-(Aminomethyl)thiophen-2-yl)sulfonyl)phenyl)-
sulfonyl)ethyl)-acetamide Hydrochloride (8j). A mixture of tert-
butyl ((5-((4-(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)-
carbamate 28 (448 mg, 1.01 mmol) and 7 N NH3 in MeOH (10
mL) was stirred at rt for 2 h. The solvent was removed under reduced
pressure to afford tert-butyl ((5-((4-((2-aminoethyl)sulfonyl)phenyl)-
thio)thiophen-2-yl)methyl)carbamate as a white solid (472 mg,
quant.), which did not required further purification. 1H NMR (500
MHz, methanol-d4) δ 7.70 (d, J = 3.8 Hz, 1H), 7.03 (d, J = 3.9 Hz,
1H), 4.39 (s, 2H), 8.16−8.12 (m, 2H), 3.39 (t, J = 6.7 Hz, 2H), 2.96
(t, J = 6.7 Hz, 2H), 1.44 (s, 9H), 8.27−8.21 (m, 2H). LCMS (ESI)
m/z 405 [M − tBu + 2H]+.
Ac2O (18.1 μL, 0.191 mmol) was added to a solution of afford tert-
butyl ((5-((4-((2-aminoethyl)sulfonyl)phenyl)thio)thiophen-2-yl)-
methyl)carbamate (80 mg, 0.174 mmol) and Et3N (29.1 μL, 0.209
mmol) in DCM (1.2 mL), and the mixture was stirred at rt for 1 h.
DCM (20 mL) was added. The organic solution was washed with
H2O (20 mL) and brine (20 mL), dried over MgSO4, and filtered,
and the solvent was removed under reduced pressure. Four molar
HCl in dioxane (5.0 mL) was added to the crude, and the mixture was
stirred at rt for 16 h. The precipitated solid was filtered through a pad
of celite and washed with EtOAc. MeOH was added to dissolve the
solid, and the suspension was filtered. The solvent was removed under
reduced pressure to afford compound 8j as a white solid (42 mg,
55%), which did not require further purification. 1H NMR (500 MHz,
methanol-d4) δ 8.26 (d, J = 8.5 Hz, 2H), 8.15 (d, J = 8.6 Hz, 2H),
7.83 (d, J = 3.9 Hz, 1H), 7.34 (d, J = 3.8 Hz, 1H), 4.39 (s, 2H), 3.57−
3.44 (m, 4H), 1.69 (s, 3H). 13C NMR (126 MHz, methanol-d4) δ
173.41, 148.05, 146.22, 145.69, 144.29, 136.17, 131.85, 130.69,
129.58, 54.98, 38.43, 34.81, 22.23. HRMS (ESI) for C15H19N2O5S3
([M + H]+): calculated 403.0451; observed 403.0453; error = 0.50
ppm.
(5-((4-((2-Methoxyethyl)sulfonyl)phenyl)sulfonyl)thiophen-
2-yl)methanamine Hydrochloride (8k). A mixture of tert-butyl
((5-((4-(vinylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)-
carbamate 28 (65.9 mg, 0.149 mmol), K2CO3 (24.6 mg, 0.178
mmol), and MeOH (1 mL) was stirred at rt for 2 h before it was
diluted with EtOAc (20 mL). The organic layer was washed with 1:1
H2O/brine (20 mL), dried over MgSO4, and filtered, and the solvent
was removed under reduced pressure. Four molar HCl in dioxane (5
mL) was added to the crude, and the mixture was stirred at rt for 3 h.
The precipitated solid was filtered through a pad of celite and washed
with EtOAc. MeOH was added to dissolve the solid, and the
suspension was filtered. The solvent was removed under reduced
pressure to afford compound 8k as a white solid (30 mg, 54%) which
did not require further purification. 1H NMR (500 MHz, methanol-
d4) δ 8.22 (d, J = 8.6 Hz, 2H), 8.13 (d, J = 8.6 Hz, 2H), 7.83 (d, J =
3.9 Hz, 1H), 7.33 (d, J = 3.9 Hz, 1H), 4.39 (s, 2H), 3.72 (t, J = 5.6
Hz, 2H), 3.55 (t, J = 5.6 Hz, 2H), 3.11 (s, 3H). 13C NMR (126 MHz,
methanol-d4) δ 147.77, 146.76, 146.08, 144.50, 136.04, 131.78,
130.69, 129.24, 66.83, 58.69, 56.78, 38.43. HRMS (ESI) for
C14H18NO5S3 ([M + H]
+): calculated 376.0342; observed
376.0333; error = 2.4 ppm.
(5-((3-(tert-Butyl)-5-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methanamine (9a). To a solution of carbaldehyde
33 (590 mg, 1.66 mmol) in THF (50 mL) at 0 °C was added sodium
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borohydride (141 mg, 3.72 mmol). The reaction mixture was stirred
at rt for 2 h, before it was quenched with ice. The pH of the solution
was adjusted to 4−5 with 1 M HCl, and the aqueous phase was
extracted with EtOAc. The combined organic phase was washed with
brine, dried over Na2SO4, and filtered, and the solvent was removed
under reduced pressure. The crude was dissolved in DCM (50 mL).
mCPBA (77%; 742 mg, 3.31 mmol) was added in small portions at 0
°C. The mixture was stirred at rt for 12 h, and the solvent was
subsequently removed under reduced pressure. The crude was
purified by chromatography (EtOAc/cyclohexane 0 → 60%) to
afford (5-((3-(tert-butyl)-5-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methanol (500 mg, 78% over two steps). 1H NMR
(500 MHz, chloroform-d) δ 8.32 (t, J = 1.4 Hz, 1H), 8.27 (t, J = 1.7
Hz, 1H), 8.13 (t, J = 1.6 Hz, 1H), 7.65 (d, J = 3.8 Hz, 1H), 6.99 (d, J
= 3.8 Hz, 1H), 4.87 (s, 2H), 3.10 (s, 3H), 2.24 (br, 1H), 1.40 (s, 9H).
13C NMR (126 MHz, chloroform-d) δ 155.4, 155.3, 143.8, 142.0,
140.2, 134.3, 129.1, 128.7, 125.0, 123.7, 60.1, 44.4, 35.8, 31.0. HRMS
(ESI) for C16H19O4S3 ([M − OH]+): calculated 371.0445; observed
371.0486.
To a solution of (5-((3-(tert-butyl)-5-(methylsulfonyl)phenyl)-
sulfonyl)thiophen-2-yl)methanol (500 mg, 1.29 mmol) in THF (15
mL) at 0 °C was added PPh3 (406 mg, 1.54 mmol) and DEAD (0.24
mL, 1.54 mmol). The mixture was stirred at 0 °C for 10 min, followed
by the addition of DPPA (0.35 mL, 1.54 mmol). The reaction was
warmed to rt over 16 h, and the solvent was removed under reduced
pressure. The crude was dissolved in EtOH (50 mL), and Pd/C
(10%; 150 mg) was added. The mixture was stirred at rt under H2
pressure (balloon) for 12 h and then filtered through celite. The
solvent was removed under reduced pressure, and the crude was
purified by chromatography (EtOH/cyclohexane 0 → 100%) to
afford compound 9a as an orange gum (262 mg, 52%). 1H NMR (500
MHz, chloroform-d) δ 8.28 (t, J = 1.4 Hz, 1H), 8.23 (t, J = 1.6 Hz,
1H), 8.09 (t, J = 1.6 Hz, 1H), 7.60 (d, J = 3.8 Hz, 1H), 6.90 (d, J = 3.8
Hz, 1H), 4.06 (s, 2H), 3.08 (s, 3H), 1.70 (br, 2H), 1.36 (s, 9H). 13C
NMR (126 MHz, chloroform-d) δ 159.4, 155.2, 143.9, 141.8, 138.6,
134.5, 128.9, 128.4, 123.9, 123.5, 44.3, 41.4, 35.6, 30.9. HRMS (ESI)
for C16H19O4S3 ([M − NH]2+): calculated 371.0445; observed
371.0428; error = 4.6 ppm.
(5-((3-(tert-Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methanamine (9b). NaOtBu (65.8 mg, 0.684
mmol) was added to a degassed mixture of 2-ethylhexyl 3-((3-(tert-
butoxy)-5-(methylthio)phenyl)thio)propanoate 60 (282 mg, 0.684
mmol) and 5-bromothiophene-2-carbonitrile 17a (76.1 μL, 0.684
mmol) in DMF (3.4 mL), and the mixture was stirred at 60 °C for 3h.
The cooled mixture was diluted with EtOAc (50 mL), washed with
H2O (3 × 50 mL) and brine (50 mL), dried over MgSO4, and filtered.
The solvent was removed under reduced pressure, and the crude was
purified by chromatography (EtOAc/pet ether 0 → 10%) to afford 5-
((3-(tert-Butoxy)-5-(methylthio)phenyl)thio)thiophene-2-carboni-
trile as a colorless oil (85 mg, 37%). 1H NMR (300 MHz, chloroform-
d) δ 7.51 (d, J = 3.9 Hz, 1H), 7.12 (d, J = 3.9 Hz, 1H), 6.94 (t, J = 1.7
Hz, 1H), 6.79 (t, J = 1.9 Hz, 1H), 6.72 (t, J = 1.9 Hz, 1H), 2.44 (s,
3H), 1.33 (s, 9H). LCMS (ESI) m/z 280 [M − tBu + 2H]+.
5-((3-(tert-Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)thiophene-
2-carbonitrile was synthesized according to general procedure GP5,
from 5-((3-(tert-Butoxy)-5-(methylthio)phenyl)thio)thiophene-2-car-
bonitrile (41 mg, 0.122 mmol), mCPBA (70−75%; 145 mg, 0.612
mmol) and DCM (1.2 mL), rt, 16 h. Chromatography (EtOAc/
cyclohexane 0 → 60%) afforded a white solid (43 g, 88%). 1H NMR
(500 MHz, chloroform-d) δ 8.17 (t, J = 1.6 Hz, 1H), 7.81 (dd, J = 2.2,
1.7 Hz, 1H), 7.76 (dd, J = 2.2, 1.6 Hz, 1H), 7.71 (d, J = 4.0 Hz, 1H),
7.60 (d, J = 4.1 Hz, 1H), 3.10 (s, 3H), 1.46 (s, 9H). LCMS (ESI, -ve)
m/z 398 [M − H]−.
Compound 9b was synthesized according to general procedure
GP3, from BH3 (1.0 M in THF; 0.53 mL, 0.53 mmol), 5-((3-(tert-
Butoxy)-5-(methylsulfonyl)phenyl)sulfonyl)thiophene-2-carbonitrile
(70 mg, 0.175 mmol) and THF (0.53 mL), 2 h, rt. Chromatography
(EtOH/cyclohexane 30, then 100%) afforded a white foam (60 mg,
85%). 1H NMR (500 MHz, methanol-d4) δ 8.14 (t, J = 1.6 Hz, 1H),
7.81 (m, 1H), 7.79−7.74 (m, 2H), 7.15 (m, 1H), 4.10 (s, 2H), 3.20
(s, 3H), 1.44 (s, 9H). 13C NMR (126 MHz, methanol-d4) δ 158.93,
157.22, 146.05, 144.77, 140.99, 136.12, 127.67, 126.97, 126.78,
120.47, 82.68, 43.97, 41.02, 28.83. HRMS (ESI) for C16H22NO5S3
([M + H]+): calculated 404.0655; observed 404.0651; error = 0.99
ppm.
(5-((3-(Methylsulfonyl)-5-((trimethylsilyl)ethynyl)phenyl)-
sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9c). A
mixture of tert-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)-
sulfonyl)thiophen-2-yl)methyl)carbamate 34 (170 mg, 0.333
mmol), Pd(PPh3)4 (38.5 mg, 10%), CuI (12.7 mg, 20%),
trimethylsilylacetylene (70.6 μL, 0.500 mmol), Et3N (0.5 mL), and
1,4-dioxane (0.5 mL) was degassed with argon and then stirred at rt
for 16 h. The solvent was removed under reduced pressure, and the
crude was dissolved in DCM (1.0 mL). Four molar HCl in dioxane
(1.0 mL) was added, and the mixture was stirred at rt for 16 h. EtOAc
(2.0 mL) was added to precipitate the solids, which were filtered,
washed with EtOAc, and dried under vacuum to afford compound 9c
as white powder (80 mg, 88%). 1H NMR (500 MHz, methanol-d4) δ
8.42 (H, 1H), 8.29−8.21 (m, 2H), 7.88 (d, J = 3.7 Hz, 1H), 7.33 (d, J
= 3.8 Hz, 1H), 4.39 (s, 2H), 3.21 (s, 3H), 0.28 (s, 9H). 13C NMR
(126 MHz, methanol-d4) δ 146.34, 145.18, 144.58, 143.96, 136.34,
136.15, 135.52, 131.87, 127.82, 126.41, 101.83, 54.75, 43.85, 38.40.
HRMS (ESI) for C17H22NO4S3Si ([M + H]
+): calculated 428.0475;
observed 428.0477; error = 0.47 ppm.
(5-((3-(1-Methyl-1H-pyrazol-4-yl)-5-(methylsulfonyl)-
phenyl)sulfonyl)thiophen-2-yl)methanamine (9d). The titled
compound was synthesized according to general procedures GP7 and
GP2, from (i) tert-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)-
sulfonyl)thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196 mmol),
Pd(PPh3)4 (22.6 mg, 10%), (1-methyl-1H-pyrazol-4-yl)boronic acid
pinacol ester (48.9 mg, 0.235 mmol), Cs2CO3 (76.7 mg, 0.235
mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in
dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h. The crude was basified
with 2 N NH3 in MeOH and purified by chromatography (MeOH/
DCM 0→ 25%) to afford a light yellow solid (57 mg, 71%). 1H NMR
(500 MHz, methanol-d4/chloroform-d) δ 8.29 (t, J = 1.7 Hz, 1H),
8.27−8.22 (m, 2H), 8.07 (s, 1H), 7.91 (s, 1H), 7.69 (d, J = 3.9 Hz,
1H), 7.04 (d, J = 3.7 Hz, 1H), 4.04 (s, 2H), 3.95 (s, 3H), 3.18 (s,
3H). 13C NMR (126 MHz, methanol-d4/chloroform-d) δ 157.51,
145.17, 143.55, 139.75, 137.56, 137.06, 135.61, 129.87, 128.63,
128.57, 126.43, 123.50, 120.52, 44.25, 41.01, 39.31. HRMS (ESI) for
C16H18N3O4S3 ([M + H]
+): calculated 412.0454; observed 412.0444;
error = 2.4 ppm.
(5-((3-(Methylsulfonyl)-5-(pyridin-4-yl)phenyl)sulfonyl)-
thiophen-2-yl)methanamine (9e). The titled compound was
synthesized according to general procedures GP7 and GP2, from
(i) tert-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196 mmol), Pd-
(PPh3)4 (45.2 mg, 20%), pyridine-4-boronic acid (57.8 mg, 0.470
mmol), Cs2CO3 (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL),
90 °C, 16 h and (ii) 4 M HCl in dioxane (0.6 mL) and 1,4-dioxane
(0.6 mL), rt, 16 h. The crude was basified with 2 N NH3 in MeOH
and purified by chromatography (MeOH/DCM 0→ 20%) to afford a
yellow solid (35 mg, 44%). 1H NMR (500 MHz, methanol-d4/
chloroform-d) δ 8.72−8.69 (m, 2H), 8.55 (t, J = 1.6 Hz, 1H), 8.50 (t,
J = 1.6 Hz, 1H), 8.45 (t, J = 1.6 Hz, 1H), 7.73−7.70 (m, 3H), 7.04 (d,
J = 3.9 Hz, 1H), 4.04 (s, 2H), 3.23 (s, 3H). 13C NMR (126 MHz,
methanol-d4/chloroform-d) δ 158.47, 150.06, 145.33, 145.14, 143.36,
141.22, 138.23, 135.26, 130.28, 130.21, 126.22, 125.35, 122.13, 43.68,
40.64. HRMS (ESI) for C17H17N2O4S3 ([M + H]
+): calculated
409.0345; observed 409.0340; error = 1.2 ppm.
(5-((4′-Methyl-5-(methylsulfonyl)-[1,1′-biphenyl]-3-yl)-
sulfonyl)thiophen-2-yl)methanamine (9g). The titled compound
was synthesized according to general procedures GP7 and GP2, from
(i) tert-butyl ((5-((3-bromo-5-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196 mmol), Pd-
(PPh3)4 (22.6 mg, 10%), p-tolyl boronic acid (32.0 mg, 0.235 mmol),
Cs2CO3 (76.7 mg, 0.235 mmol), and 1,4-dioxane (1.3 mL), 90 °C, 16
h and (ii) 4 M HCl in dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h.
The crude was basified with 2 N NH3 in MeOH and purified by
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chromatography (acetone/DCM 0 → 40%) to afford a light yellow
foam (20 mg, 24%). 1H NMR (500 MHz, chloroform-d) δ 8.45−8.39
(m, 2H), 8.30 (t, J = 1.6 Hz, 1H), 7.67 (d, J = 3.9 Hz, 1H), 7.54 (d, J
= 8.2 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 6.93 (d, J = 3.9 Hz, 1H), 4.09
(s, 2H), 3.14 (s, 3H), 2.44 (s, 3H), 1.61 (s, 2H). 13C NMR (126
MHz, chloroform-d) δ 144.95, 144.56, 142.77, 139.79, 138.73,
134.92, 134.43, 130.27, 130.15, 129.73, 127.25, 124.34, 124.16, 44.59,
41.71, 21.36. HRMS (ESI) for C19H20NO4S3 ([M + H]
+): calculated
422.0549; observed 422.0561; error = 2.8 ppm.
(5-((3′,5′-Dimethyl-5-(methylsulfonyl)-[1,1′-biphenyl]-3-yl)-
sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9h). The
titled compound was synthesized according to general procedures
GP7 and GP2, from (i) tert-butyl ((5-((3-bromo-5-(methylsulfonyl)-
phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196
mmol), Pd(PPh3)4 (22.6 mg, 10%), (3,5-dimethylphenyl)boronic
acid (35.3 mg, 0.235 mmol), Cs2CO3 (76.7 mg, 0.235 mmol), and
1,4-dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (0.7
mL) and 1,4-dioxane (0.7 mL), rt, 16 h. The crude was basified with 2
N NH3 in MeOH and purified by chromatography (EtOH/
cyclohexane 0 → 100% then 100%) to afford a white solid (23 mg,
27%). 1H NMR (500 MHz, methanol-d4/chloroform-d) δ 8.41−8.35
(m, 2H), 8.30 (t, J = 1.6 Hz, 1H), 7.68 (d, J = 3.9 Hz, 1H), 7.22 (br,
2H), 7.09 (br, 1H), 7.03 (d, J = 3.8 Hz, 1H), 4.04 (s, 2H), 3.17 (s,
3H), 2.38 (s, 6H). 13C NMR (126 MHz, methanol-d4/chloroform-d)
δ 145.50, 144.81, 143.06, 139.62, 139.57, 137.51, 135.39, 131.47,
130.63, 130.52, 126.17, 125.50, 124.57, 44.43, 40.89, 21.44. HRMS
(ESI) for C20H22NO4S3 ([M + H]
+): calculated 436.0705; observed
436.0700; error = 1.1 ppm.
(5-((2′-Ethyl-5-(methylsulfonyl)-[1,1′-biphenyl]-3-yl)-
sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9i). The
titled compound was synthesized according to general procedures
GP7 and GP2, from (i) tert-butyl ((5-((3-bromo-5-(methylsulfonyl)-
phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 34 (100 mg, 0.196
mmol), Pd(PPh3)4 (22.6 mg, 10%), (2-ethylphenyl)boronic acid
(35.3 mg, 0.235 mmol), Cs2CO3 (76.7 mg, 0.235 mmol), and 1,4-
dioxane (1.3 mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (0.7 mL)
and 1,4-dioxane (0.7 mL), rt, 16 h. The crude was basified with 2 N
NH3 in MeOH and purified by chromatography (EtOH/cyclohexane
0 → 100% then 100%) to afford a white foam (42 mg, 49%). 1H
NMR (500 MHz, chloroform-d) δ 8.49 (t, J = 1.7 Hz, 1H), 8.21 (t, J
= 1.6 Hz, 1H), 8.09 (t, J = 1.6 Hz, 1H), 7.66 (d, J = 3.8 Hz, 1H), 7.42
(td, J = 7.6, 1.3 Hz, 1H), 7.37 (m, 1H), 7.30 (td, J = 7.4, 1.4 Hz, 1H),
7.18 (dd, J = 7.6, 1.2 Hz, 1H), 6.94 (d, J = 3.9 Hz, 1H), 4.10 (s, 2H),
3.14 (s, 3H), 2.53 (q, J = 7.5 Hz, 2H), 1.61 (s, 2H), 1.12 (t, J = 7.6
Hz, 3H). 13C NMR (126 MHz, chloroform-d) δ 159.97, 145.25,
144.31, 142.19, 141.50, 138.66, 137.63, 134.95, 132.72, 132.24,
129.87, 129.41, 129.33, 126.37, 124.59, 124.15, 44.53, 41.73, 26.17,
15.73. HRMS (ESI) for C20H22NO4S3 ([M + H]
+): calculated
436.0705; observed 436.0727; error = 5.0 ppm.
(5-((3-(1-Methyl-1H-pyrazol-4-yl)-4-(methylsulfonyl)-
phenyl)sulfonyl)thiophen-2-yl)methanamine Dihydrochloride
(9j). The titled compound was synthesized according to general
procedures GP7 and GP2, from (i) tert-butyl ((5-((3-bromo-4-
(methylsulfonyl)phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 37
(150 mg, 0.294 mmol), Pd(PPh3)4 (34.0 mg, 10%), (1-methyl-1H-
pyrazol-4-yl)boronic acid pinacol ester (73.0 mg, 0.353 mmol),
Cs2CO3 (115 mg, 0.353 mmol), and 1,4-dioxane (2.0 mL), 90 °C, 16
h and (ii) 4 M HCl in dioxane (1.5 mL) and DCM (1.5 mL), rt, 3 h.
A white solid was obtained (111 mg, 92%). 1H NMR (500 MHz,
D2O) δ 8.32 (d, J = 8.5 Hz, 1H), 8.16 (dd, J = 8.6, 2.2 Hz, 1H), 8.05
(d, J = 1.9 Hz, 1H), 7.92 (s, 1H), 7.84 (d, J = 4.0 Hz, 1H), 7.74 (s,
1H), 7.33 (d, J = 4.0 Hz, 1H), 4.44 (s, 2H), 3.96 (s, 3H), 2.96 (s,
3H). 13C NMR (126 MHz, D2O) δ 144.87, 144.70, 142.07, 140.32,
139.70, 135.77, 134.00, 132.82, 131.38, 130.83, 130.08, 126.31,
116.55, 41.49, 38.31, 37.18. HRMS (ESI) for C16H18N3O4S3 ([M +
H]+): calculated 412.0454; observed 412.0441; error = 3.2 ppm.
(5-((6-(Methylsulfonyl)-[1,1′-biphenyl]-3-yl)sulfonyl)-
thiophen-2-yl)methanamine (9k). The titled compound was
synthesized according to general procedures GP7 and GP2, from
(i) tert-butyl ((5-((3-bromo-4-(methylsulfonyl)phenyl)sulfonyl)-
thiophen-2-yl)methyl)carbamate 37 (150 mg, 0.294 mmol), Pd-
(PPh3)4 (34.0 mg, 10%), phenylboronic acid (43.1 mg, 0.353 mmol),
Cs2CO3 (115 mg, 0.353 mmol), and 1,4-dioxane (2.0 mL), 90 °C, 16
h. Chromatography (EtOAc/DCM 0 → 100%), white foam, 169 mg
and (ii) 4 M HCl in dioxane (1.0 mL) and DCM (1.0 mL), rt, 3 h.
The crude was basified with 2 N NH3 in MeOH and purified by
chromatography (EtOH/cyclohexane 0 → 100%) to afford a white
solid (66 mg, 55%). 1H NMR (500 MHz, chloroform-d) δ 8.37 (d, J =
8.3 Hz, 1H), 8.11 (dd, J = 8.3, 1.9 Hz, 1H), 7.97 (d, J = 2.0 Hz, 1H),
7.63 (d, J = 3.9 Hz, 1H), 7.55−7.41 (m, 5H), 6.93 (d, J = 3.8 Hz,
1H), 4.10 (s, 2H), 2.61 (s, 3H), 1.63 (s, 2H). 13C NMR (126 MHz,
chloroform-d) δ 160.04, 146.65, 143.39, 142.92, 138.54, 136.79,
134.97, 131.05, 130.11, 129.70, 129.38, 128.43, 126.64, 124.12, 43.13,
41.67. HRMS (ESI) for C18H18NO4S3 ([M + H]
+): calculated
408.0392; observed 408.0373; error = 4.9 ppm.
(5-((4′-Methyl-6-(methylsulfonyl)-[1,1′-biphenyl]-3-yl)-
sulfonyl)thiophen-2-yl)methanamine Hydrochloride (9l). The
titled compound was synthesized according to general procedures
GP7 and GP2, from (i) tert-butyl ((5-((3-bromo-4-(methylsulfonyl)-
phenyl)sulfonyl)thiophen-2-yl)methyl)carbamate 37 (150 mg, 0.294
mmol), Pd(PPh3)4 (34.0 mg, 10%), p-tolyl boronic acid (48.0 mg,
0.353 mmol), Cs2CO3 (115 mg, 0.353 mmol), and 1,4-dioxane (2.0
mL), 90 °C, 16 h and (ii) 4 M HCl in dioxane (1.5 mL) and DCM
(1.5 mL), rt, 3 h. A beige solid obtained (83 mg, 62% over). 1H NMR
(500 MHz, methanol-d4) δ 8.37 (d, J = 8.4 Hz, 1H), 8.22 (dd, J = 8.4,
2.0 Hz, 1H), 7.91 (d, J = 2.0 Hz, 1H), 7.83 (d, J = 3.9 Hz, 1H), 7.36−
7.30 (m, 5H), 4.40 (s, 2H), 2.70 (s, 3H), 2.43 (s, 3H). 13C NMR (75
MHz, methanol-d4) δ 147.21, 146.24, 145.44, 144.69, 144.29, 140.60,
136.19, 135.39, 132.22, 131.88, 131.03, 130.92, 129.94, 127.81, 43.41,
38.43, 21.30. HRMS (ESI) for C19H20NO4S3 ([M + H]
+): calculated
422.0549; observed 422.0531; error = 4.3 ppm.
Pan Assay Interference Compound (PAINS) Assessment. To
identify compounds that may demonstrate some degree of
promiscuity in biochemical screening, the PAINS filters as described
by Baell and Holloway23 were curated as SMARTS and scripted as a
flagging protocol deployed in Vortex (version 2018.09.76561.53-s,
2018, https://www.dotmatics.com/products/vortex) and Pipeline
Pilot (Dassault System̀es BIOVIA, BIOVIA Pipeline Pilot, Release
2018, San Diego: Dassault System̀es, 2018). The 480 patterns were
used to recognize structures that may result in nonspecific binding to
multiple biological targets by virtue of being comprised of one or
more fragments established to be of concern. No LOX inhibitor in
this study showed any potential PAINS liability when screened against
this PAINS filter.
LOX Protein Preparation and Enzyme Assay. LOX enzyme
was extracted from pig skin by the method of Shackleton and
Hulmes.24 LOX catalytic activity was determined using a horseradish
peroxidase (HRP)-coupled fluorescent assay previously described,19
with cadaverine hydrochloride as a substrate, BAPN as positive
control, and a preincubation time of 20 min with nine dilutions from a
top concentration of 100 μM. LOXL2 was purchased from R&D
System. LOXL2 catalytic activity was determined using the Promega
ROS-Glo assay kit with cadaverine hydrochloride as a substrate,
BAPN as positive control, and a preincubation time of 20 min at the
same concentrations as above.
High-Throughput Screening. HTS was performed by Evotec
AG on 270 000 diverse compounds and 5000 fragments using the
enzyme assay described above.
Amine Oxidase Assays. Methods for the determination of
catalytic activity of DAO, MAO-A, and MAO-B have been previously
described.19 All amine oxidase assays were performed with
concentrations as above. MAO-A and MAO-B enzymes were
purchased from Promega and Sigma, respectively. The catalytic
activity of MAO-A and MAO-B was determined using the Promega
MAO-Glo assay kit (substrate included), with clorgyline and deprenyl
as positive controls, respectively. DAO was purchased from Sigma and
the catalytic activity was determined using the Promega ROS-Glo
assay kit, with aminoguanidine as the positive control. SSAO was
purchased from Sigma. SSAO catalytic activity was determined using
the Promega MAO-Glo assay kit, with Mofegiline as positive control.
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Assessment of Compound 9f as a Substrate for Amine Oxidases.
The catalytic activities of MAO-A, MAO-B, and SSAO with
compound 9f as a substrate were determined using the respective
enzymes described above, and the hydrogen peroxide produced was
quantified using the HRP-coupled fluorescent method as in the LOX
activity assay.
MLM Stability Assay. Mouse liver microsomes (BALB/c) were
purchased from Tebu-bio, and the assay was performed by methods
previously described.19 Inhibitors at 10 μM concentration incubated
with the microsomes were assessed at 0, 15, and 30 min. Control
samples containing no microsomes and no cofactors were also
assessed at 0 and 30 min. Samples were extracted by protein
precipitation and centrifugation for 20 min in a refrigerated centrifuge
(4 °C) at 3700 rpm. The supernatant was analyzed by LCMS/MS for
% metabolized over time.
In Vivo PK. All procedures involving animals were performed in
accordance with national Home Office regulations under the Animals
(Scientific Procedures) Act 1986 and within guidelines set out by the
Institute’s Animal Ethics Committee and the United Kingdom
Coordinating Committee for Cancer Research’s ad hoc Committee
on the Welfare of Animals in Experimental Neoplasia.25 Female
BALB/c or CD1 mice (Charles River Laboratories) at 6 weeks of age
were used for the PK analyses. The mice were dosed orally by gavage
(50 mg/kg in dimethyl sulfoxide (DMSO)/water 1:19 v/v; n = 21) or
intravenously in the tail vein (10 mg/kg in DMSO/Tween20/saline
10:1:89 v/v/v; n = 24). Samples were taken at seven (po) or eight
(iv) time points between 5 min and 24 h. Three mice were used per
time point per route. They were placed under halothane or isoflurane
anesthesia, and blood for plasma preparation was taken by terminal
cardiac puncture into heparinized syringes. Plasma samples were snap-
frozen in liquid nitrogen and then stored at −80 °C prior to analysis.
In Vivo Anti-metastatic Efficacy. LOX inhibitor treatment was
carried out in mouse GEMM breast cancer model where MMTV-
PyMT female mice were randomized as described previously.19 Mice
were treated daily by oral gavage with 70 mg/kg compound 9f (n = 5)
in vehicle (5% DMSO/2.5% Tween20 in water) or control with
vehicle alone (n = 7). Lungs were collected at the end of the
experiment, as previously described.19
Histology and Immunohistochemistry. All mouse tissue
samples were fixed in 10% formalin (Sigma) and embedded in
paraffin. For spontaneous lung metastasis in MMTV-PyMT animals,
the number of metastasis in the lung parenchyma was counted and
the size was measured.
Commercial ADME-T Services. hERG inhibition was deter-
mined using the “hERG Human Potassium Ion Channel Cell Based
Antagonist Qpatch Assay” by Eurofins Ltd. Cell permeability was
determined using the “Caco-2 permeability assay” by Cyprotex Ltd.
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AMT, aminomethylenethiophene; BAPN, 3-aminopropioni-
trile; DAO, diamine oxidase; dba, dibenzylideneacetone; CL,
clearance; Cmax, maximal concentration; DIPEA, N,N-diiso-
propylethylamine; DPPA, diphenyl phosphoryl azide; GEMM,
genetically engineered mouse model; HMDS, hexamethyldisi-
lazane; HRP, horseradish peroxidase; LOX, lysyl oxidase;
LOXL, lysyl oxidase like; LTQ, lysine tyrosylquinone; MAO,
monoamine oxidase; mCPBA, meta-chloroperbenzoic acid;
MLM, mouse liver microsome; MMTV, mouse mammary
tumor virus; PAINS, pan assay interference compounds;
PyMT, polyomavirus middle T-antigen; ROS, reactive oxygen
species; SSAO, semicarbazide-sensitive amine oxidase
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